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ABSTRACT  
Introduction: Cervical carcinoma is the commonest tumour in Ugandan women. However, very 
little is known in the Ugandan population about HPV types associated with invasive cervical 
cancer, the relative risk of cervical cancer associated with different HPV types, and whether the 
risk of cervical cancer associated with HPV infection is modified by HIV infection. Furthermore, 
the nature of HPV negative invasive cervical cancer, especially adenocarcinoma, is yet to be 
described and studied to find if the use of different types of cervical samples can influence the 
studies’ results. 
 
Objectives: To study HPV types associated with invasive cervical cancer. To estimate the 
relative risk for infections with different HPV types, and whether this is modified by HIV 
infection. To describe the nature of HPV negative cancer, especially adenocarcinoma, and study 
if the use of different invasive cervical cancer samples can influence the studies’ results. 
 
Subjects and Methods: We conducted studies using 186 archival cases of cervical carcinoma 
diagnosed between 1967 and 1980, 316 new incident cases of cervical cancer and exfoliated 
cervical cells from 314 control women from Uganda between September 2004 and December 
2006. HPV testing was done using the SPF10 LiPA technology. In paper I, we assessed the 
prevalence and HPV types. For Article II, we used different antibodies to clarify the nature of 
HPV negative adenocarcinomas. In Article III, we estimated the odds ratio (OR) of cervical 
cancer for different HPV infections as well as for HIV infection. In Article IV, we compared 
HPV detection in formalin-fixed paraffin embedded (FFPE) and fresh samples.  
 
Results: In Article I, Out of the 186 cases of confirmed invasive cervical cancer in the study 
paraffin blocks, 114 were positive for HPV DNA. Specific HPV genotypes were identifiable in 
109 cases: HPV 16, 18, 31, 35, 39, 44, 45, 51, 52 and 70. These occurred as single infections in 
105 cases (96.3%) and as multiple infections in 4 cases (3.7%). HPV 16 or 18 accounted for 80% 
(84/105) of cases with a single infection. 
In Article II, Among the 13/25 HPV negative ADC samples, five were positive for CEA, 
suggesting endocervical origin, and three were vimentin positive (one had a mucinous 
endocervical histological pattern and two were ADC, not otherwise specified, most likely of 
endometrial origin). In Article III, we found a high relative risk of both squamous cell carcinoma 
and adenocarcinoma of the cervix with HPV 16 and 18, and moderate relative risk with HPV 45. 
Concurrent infection with HIV did not increase the relative risk with these three HPV types, but 
was associated with a statistically borderline increased relative risk of squamous cervical 
carcinoma only with low-risk types and multiple infections with HPV types.  
Article IV showed comparable HPV detection in both fresh and FFPE tissue by the SPF10 LiPA 
method, with complete agreement for 59.7%, partial agreement 5.3% and complete disagreement 
35.0%. 
 
Conclusion: Most cervical carcinomas in Uganda are associated with high-risk HPV types, and 
concurrent infection with HIV has little impact. Both archival and fresh samples are suitable for 
HPV detection, and the use of antibodies may be useful in the characterization of HPV negative 
cervical adenocarcinomas. 
 
Key words: HPV, Human Papillomaviruses, women, HIV, Uganda, invasive cervical cancer. 
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ABSTRACT  
 Introduction: Cervical carcinoma is the commonest tumour in Ugandan women. However, 
very little is known in the Ugandan population about HPV types associated with invasive 
cervical cancer, the relative risk of cervical cancer associated with different HPV types, and 
whether the risk of cervical cancer associated with HPV infection is modified by HIV infection. 
Furthermore, the nature of HPV negative invasive cervical cancer, especially adenocarcinoma, 
is yet to be described and studied to find if the use of different types of cervical samples can 
influence the studies’ results. 
Objectives: To study HPV types associated with invasive cervical cancer. To estimate the 
relative risk for infections with different HPV types, and whether this is modified by HIV 
infection. To describe the nature of HPV negative cancer, especially adenocarcinoma, and study 
if the use of different invasive cervical cancer samples can influence the studies’ results. 
Subjects and Methods: We conducted studies using 186 archival cases of cervical carcinoma 
diagnosed between 1967 and 1980, 316 new incident cases of cervical cancer and exfoliated 
cervical cells from 314 control women from Uganda between September 2004 and December 
2006. HPV testing was done using the SPF10 LiPA technology. In paper I, we assessed the 
prevalence and HPV types. For Article II, we used different antibodies to clarify the nature of 
HPV negative adenocarcinomas. In Article III, we estimated the odds ratio (OR) of cervical 
cancer for different HPV infections as well as for HIV infection. In Article IV, we compared 
HPV detection in formalin-fixed paraffin embedded (FFPE) and fresh samples.  
Results: In Article I, Out of the 186 cases of confirmed invasive cervical cancer in the study 
paraffin blocks, 114 were positive for HPV DNA. Specific HPV genotypes were identifiable in 
109 cases: HPV 16, 18, 31, 35, 39, 44, 45, 51, 52 and 70. These occurred as single infections in 
105 cases (96.3%) and as multiple infections in 4 cases (3.7%). HPV 16 or 18 accounted for 
80% (84/105) of cases with a single infection. 
In Article II, Among the 13/25 HPV negative ADC samples, five were positive for CEA, 
suggesting endocervical origin, and three were vimentin positive (one had a mucinous 
endocervical histological pattern and two were ADC, not otherwise specified, most likely of 
endometrial origin). In Article III, we found a high relative risk of both squamous cell 
carcinoma and adenocarcinoma of the cervix with HPV 16 and 18, and moderate relative risk 
with HPV 45. Concurrent infection with HIV did not increase the relative risk with these three 
HPV types, but was associated with a statistically borderline increased relative risk of squamous 
cervical carcinoma only with low-risk types and multiple infections with HPV types.  
Article IV showed comparable HPV detection in both fresh and FFPE tissue by the SPF10 
LiPA method, with complete agreement for 59.7%, partial agreement 5.3% and complete 
disagreement 35.0%. 
Conclusion: Most cervical carcinomas in Uganda are associated with high-risk HPV types, and 
concurrent infection with HIV has little impact. Both archival and fresh samples are suitable for 
HPV detection, and the use of antibodies may be useful in the characterization of HPV negative 
cervical adenocarcinomas. 
Key words: HPV, Human Papillomaviruses, women, HIV, Uganda, invasive cervical cancer. 
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1 INTRODUCTION 
 
In Uganda, cervical carcinoma is one of the commonest tumors affecting women. Data from the 
Kampala Cancer Registry (K.C.R) in the fifties showed the incidence was 12.6/100,000 [1]. 
Subsequent results for the period 1960 to 1997, showed the incidence increasing from 22 in the 
1960s to 40/100,000 in the 1990s [2] and has now risen to 52.4 per 100,000 women [3]. Whether 
the increase could be partially attributed to the prevailing AIDS epidemic remains unclear. Earlier 
studies done in Uganda [4] and Tanzania [5] found no association between cervical cancer risk and  
Human immunodeficiency virus (HIV), while more recent studies from Uganda showed marginal 
increased relative risk of cervical cancer among women who are HIV positive [6, 7].    
This apparent discrepancy is difficult to explain, but could be due to the lack of early detection and 
screening programs for cervical cancer, and the relatively short life expectancy of HIV positive 
women, in particular before the introduction or anti-retroviral drugs. Thus, it is plausible that a 
significant percentage of HIV-positive women could die before developing cervical carcinoma in 
many countries in Sub-Saharan Africa, including Uganda. 
Despite the high incidence of cervical carcinoma in Uganda, not much is known about Human 
papillomavirus (HPV) types associated with it, although a number of studies have been carried out 
on different aspects of HPV and cervical cancer [4, 6-9]. It is therefore important to estimate the 
relative risk of cervical carcinoma with different HPV and the effect of HIV infection on the risk in 
the Ugandan population as well as to clarify the nature of HPV negative cervical cancers, especially 
adenocarcinoma. These are important background for the development and evaluation of future 
HPV vaccines. 
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This thesis is composed of 4 original scientific articles, namely:  
 
Article I. HPV type distribution in invasive cervical cancer in Uganda. 
 
Article II. The usefulness of immunohistochemistry in tissue microarrays of human 
papillomavirus negative adenocarcinoma of the uterine cervix. 
 
Article III. HPV types, HIV and invasive cervical carcinoma risk in Kampala, Uganda: a case 
control study. 
 
Article IV. Comparison of human papillomavirus (HPV) detection between fresh tissue and 
paraffin embedded blocks of invasive cervical cancer. 
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2 BACKGROUND 
 
2.1 OVERVIEW OF HUMAN PAPILLOMAVIRUS (HPV) 
 
HPV are DNA viruses belonging to the Papillomaviridae family. To date, more than 100 HPV 
types have been described, and many have their genomes partially or fully sequenced [10]. Despite 
their marked diversity, HPV share a common genetic organization. The circular DNA genomic 
structure is divided into three parts. The first part is known as the non-coding regulatory region, 
also termed the up-stream regulatory region (URR) or long control region (LCR), and it modulates 
viral replication and gene transcription. The second part is the HPV early genes (E1, E2, E4, E5, 
E6, and E7), which code for proteins involved in viral replication, viral transcription and regulation 
of infected cell proliferation. The last part is the late region composed of two genes (L1 and L2) 
that code for the minor and major capsid viral proteins.  
HPV are divided into 16 genera, with the alpha- and beta-papillomaviruses being associated with 
human lesions. The alpha-papillomaviruses are associated with most ano-genital lesions [10]. HPV 
types that were initially detected from benign lesions were classified as low-risk types, while those 
detected from malignant lesions were designated as high- risk types. 
 
2.2 HPV DETECTION METHODS 
 
A number of methods have been developed to detect HPV, the most widely used being PCR-based 
protocols using primers that are directed against the highly conserved region of the L1 gene and 
which are able to detect many mucosal HPV types (Bernard et al., 1994). The GP5+/6+ system [11] 
utilizes 150 bp primers, while the MY09/11 primer [12] and primer derivatives use 450 bp primers 
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[13]. The primers for SPF10-PCR assay [14, 15] use primers which are 65 bp and are more specific 
compared to the others.     
The other PCR-based methods are the hybrid capture systems. The Hybrid Capture 2 HPV DNA 
test (hc2) (Digene Corporation, Gaithersburg, MD), a microplate-based solution and solid phase 
hybridization assay for the detection of 13 high-risk (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 
68) and five low-risk (6, 11, 42, 43, 44) HPVs, is at present the only FDA approved assay for the 
routine detection of HPV infections and the only commercially available HPV DNA assay with 
sufficient scientific data to support its performance in a clinical setting (2, 6, 7). 
Other molecular methods include Southern blot (SB), dot blot (DB) and in situ hybridization (ISH). 
With the exception of ISH, which is popular among pathologists because of its direct visualisation 
effects, SB and DT have been mainly replaced by PCR methods.  
 
2.3 HPV AND CERVICAL CARCINOMA 
 
Clinical and epidemiological studies have clearly established that infections by certain human 
papillomaviruses (HPVs) types, so-called high-risk types, are intimately linked to cervical cancer 
development. Several types of HPVs, especially types 16 and 18, are recognized as the main causes 
of cervical cancer and its precursor lesions [16].  These two viral types were found in most cases of 
invasive cervical cancer from 22 countries around the world [17].  
 
From earlier studies, HPV were classified into high-risk (HR type) or low-risk (LR type) based on 
their isolation from malignant or benign lesions [18, 19] ,while taxonomic classification is based on 
DNA sequences of the L genes [10]. Using epidemiologic approaches, Muñoz et al. [20] classified 
HPV into high-risk types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73 and 82), probably 
 11 
 
high-risk types (26, 53 and 66), low-risk types (6, 11, 40, 42, 43, 44, 54, 61, 70, 72 and CP6108) 
and lastly some as undetermined risk types (34, 57 and 83). The risk of cervical carcinoma 
associated with HPV varies in different studies.  Franceschi et al. [21] assessed the risk of cervical 
carcinoma in India and found an OR of 497.9 (95% CI: 67.7-999) for any positive HPV.  
Castellsagué et al. [22] assessed the risk of cervical adenocarcinoma and found increased relative 
risk for any HPV positive (OR 81.27, 95% CI: 42.04-571.1), HPV 16 (OR 164.12, 95% CI: 
76.09-354) and HPV 18 (OR 410, 95% CI: 167.44-∞). In a recent study from Mexico, Illades-
Aguiar et al. [23] also found high ORs, varying from 34.9 (95% CI: 2.8-∞) for low-risk HPV to 
804.4 (95% CI: 71.1-∞) for HPV 18. 
There are relatively few studies that have assessed the risk of cervical carcinoma in relation to 
HPV and HIV. Hawes et al. [24] found increased relative risk of cervical carcinoma for high- risk 
HPV types in association with HIV infection, with ORs of 2.2 (95% CI: 1.0-4.8) for HIV1, 6.0 
(95% CI: 2.1-17.1) for HIV2 and 8.0 (95% CI: 2.0-31.5) for HIV1 and 2.  
 A number of HPV types have been identified in cervical carcinoma from different studies, with 
HPV 16 and 18 occurring in more than 50% of the cases, with geographical variations. A large 
worldwide study was done by Bosch et al. in the early nineties [17]. Over 1000 cases of invasive 
cervical carcinoma from 22 countries were analyzed. HPV DNA was detected in 93% of the cases. 
Overall, HPV 16 was predominant in all countries except Indonesia, where HPV 18 was 
predominant. In a study from China, Chen et al. [25] analyzed 664 cases of invasive cervical 
carcinoma (630 SCC, 34 ADC) and 569 CIN 2/3 from seven regions of China. HPV was detected 
in 97.6% of invasive cancer, with HPV 16 being the most common. 
In a pooled analysis of 10,058 cases (8550 SCC, 1508 ADC) [26], the most common HPV types 
in ICC were, in order of decreasing prevalence, HPV 16, 18, 45, 31, 33, 58, 52, 35, 59, 56, 6, 51, 
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68, 39, 82, 73, 66 and 70. In SCC, HPV 16 was the predominant type (46-63%), while in ADC 
HPV 18 was the predominant type in every region (37-41%). In studies restricted to ADC only, 
the HPV prevalence was high. Castellsagué et al. [22] found HPV 16 and 18 were present in 82% 
of cases, while An et al. [27] found 78% of ADC had HPV 16 or 18. 
 
2.4 TYPES OF CERVICAL CARCINOMA 
 
Cervical carcinoma comprises of squamous cell carcinoma, adenocarcinoma and other types. 
Squamous cell carcinoma is the commonest type, accounting for more than 70% of cases. HPV 16 
tends to predominate in squamous cell carcinoma, while HPV 18 types are usually found in 
adenocarcinomas. Though these two types are associated with the two histological types, other 
types of HPV have also been identified in these histological types. While the diagnosis of SCC is 
usually straightforward, the nature of adenocarcinomas in the cervix may be difficult to ascertain 
whether of cervical or endometrial origin.   
 
There are also some rare types of cervical carcinoma, namely one resembling lympho-epithelioma   
[28, 29]. Etiologically, some are thought to be related to EBV [30], with some being negative for 
HPV [31]. They are more common in Asian women than Caucasians [32]. Other unusual forms of 
cervical carcinoma are papillary squamous cell carcinoma [33-35]. Unusual types of 
adenocarcinoma include glassy cell carcinoma [36], clear cell, serous, and mesonephric carcinomas 
[37].  
 
2.5 MECHANISMS OF HPV CARCINOGENESIS 
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The roles of HPV in cervical carcinoma are thought to be through interference with p53 and 
retinoblastoma gene product. The E6-p53 interaction results in the accelerated degradation of p53 
in vitro via the ubiquitin-dependent proteolysis system [38, 39], while the E7 complexes with pRB 
[38], the affinity of HR HPV being ten times that of other HPV [40]. Use of the E7-E6 fusion 
proteins of HPV 6 and HPV 11 have also been shown to promote the degradation of the 
retinoblastoma protein [41], indicating that the property to target associated proteins for 
degradation is shared by the anogenital specific HPV E6 proteins. In addition to interference with 
p53 and pRB pathways, the E6 and E7 HPV proteins induce chromosomal alterations [42].  
The inhibition of the retinoblastoma gene leads to accumulation of p16 [43] and this has been 
used as a surrogate marker of HPV infection [44] and also as a marker of E7 gene activity [45]. 
 
2.6 HPV NEGATIVE CERVICAL CARCINOMA  
 
Although many cases of cervical carcinomas are associated with HPV, there are cases where HPV 
have not been detected. Liebrich et al. [46] described four cases of HPV negative cervical 
carcinoma in 14 to 20 years old cases out of 5,878 cervical carcinoma cases. They also found 14 
cases in a literature search. Pirog et al. [37] earlier noted that some rare types of endocervical 
adenocarcinoma were negative for HPV DNA. Kanao et al have shown that over-expression of 
p14(ARF) and p16(INK4A) was strongly associated with HPV positive cervical carcinoma, while 
reduced expression of p14 and p16 correlated with HPV negative cervical cancer [47]. 
Abnormalities of G1 pathway may also be one important mechanism of carcinogenesis of HPV 
negative cervical carcinoma [48]. 
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2.7 MECHANISMS OF EVASION OF IMMUNE SYSTEM BY HPV 
 
HPV appears able to evade the immune system, although the exact mechanisms are not clear. A 
number of mechanisms for evasion of the immune system have been suggested. Tindle [49] 
suggested this could be due to avoidance of immune response by HPV. Other ways include 
inhibition of MHC by E6 and E7 proteins [50, 51], manipulation of Langerhan cells by minor 
capsid proteins [52], inhibition of transcription factors [51] and subverting the immune response 
[49, 53]. It has also been experimentally shown that HPV 16 interferes with innate immunity by 
affecting TLR9 expression and function [54]. In addition to evasion of the immune system, HPV 
may persist in the cervix because it could be an immune privilege site [55].  
 
2.8 COFACTORS IN CERVICAL CARCINOGENESIS 
 
It is well known that HPV is essential, but not sufficient, to cause cervical carcinoma. Other 
cofactors are necessary. In addition to factors associated with lifestyle, a number of cofactors have 
been studied, namely, Clamydiae trachomatis [56, 57], hormonal factors [58-60] and immune 
deficient states [61-64] and many others. Immune deficient states have aroused much attention by 
finding increased relative risk of tumours in transplant recipients [65-70]. 
 
2.8.1 Cofactors associated with HPV acquisition 
From earlier observations, it was noted that cervical carcinoma was very rare in nuns and virgins, 
but much more common in prostitutes (summarized by zur Hausen, 2009) [71]. This could be 
explained by acquisition of the causative agent through sexual intercourse. These were 
subsequently confirmed by additional studies who found increased relative risk of cervical 
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carcinoma in association with early age at first sexual contact, multiple sexual partners, women 
whose husband has multiple sexual partners, educational status, etc. Studies have shown that two 
out of three people who have sexual intercourse with a HPV positive person acquire the infection 
[72]. 
 
2.8.2 Cofactors associated with HPV persistence 
A number of studies have demonstrated increased relative risk of cervical carcinoma in women 
exposed to certain situations. These include, for example, hormonal contraceptives, smoking and 
immune suppression due to a number of agents.  
 
2.9 HORMONES AND CERVICAL CARCINOMA RISK 
 
Sex hormones have been implicated in HPV associated carcinogenesis [73]. In a pooled analysis on 
reproductive factors, oral contraceptive use and HPV, it was suggested that these could be involved 
in the transition from HPV infection to neoplastic cervical lesions [74] and not HPV prevalence. 
  
2.10 CERVICAL CARCINOMAS IN ASSOCIATION WITH IMPAIRED IMMUNE 
SYSTEM 
 
2.10.1 Risks of cervical carcinoma in transplants recipients 
A number of studies have assessed the risk of cervical carcinoma in organ transplant recipients 
[67]. Most of the studies found statistically significant increased risk of cervical carcinoma as 
shown in the tables below. A surprising result was noted by Adami et al. [65] who found a non-
statistically increased risk of cervical carcinoma, but noted a much higher risk for vulva and vagina 
carcinoma. 
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Table 2.1 Relative Risk of cervical carcinoma in transplant recipients. 
Author [ref] Year No cases Relative Risk 95% CI 
Adami et al. [65] 2003 5 2.0 0.7-4.7 
Busnach et al. [66] 2006 3 3.3 0.7-9.7 
Kessler et al. [67] 2006 6 25.28 9.27-55.02 
Meeuwis et al. [68] 2009 1 3.2 - 
Schulz et al. [75] 2009 3 studies 2.13 1.37-3.30 
Serraino et al. [69] 2006 3 3.3 0.7-9.7 
Srisawat et al. [70] 2008 2 789.83 88.76-2851.16 
 
2.10.2 Risks of cervical carcinoma in HIV infection 
With the advent of the AIDS epidemic, an increased incidence of tumours, especially Kaposi’s 
sarcoma, was observed as a consequence of immunodeficiency [76]. Extending this approach, a 
number of investigators assessed the possible role of HIV in cervical carcinoma. Some studies from 
developed countries have found increased relative risk of cervical carcinoma in association with 
HIV as shown in the tables below.  
 
Table 2.2 Relative Risk (OR) of cervical carcinoma associated with HIV. 
Author [ref] Year No cases Relative Risk (OR) 95% CI 
Biggar et al. [77] 2007  1.41 0.81-2.46 
Busnach et al. [66] 2006 22 14.6 9.1-22.1 
Frish et al. [78] pre AIDS 2000 44 5.4 3.9-7.2 
Frish et al. [78] post AIDS 2000 15 5.1 2.9-8.5 
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Serraino et al. [69] 2007 22 14.6 9.1-22 
 
 
Table 2.3 Standardized Incidence Rates (SIR) of cervical carcinoma associated with HIV. 
Author [ref] Year No cases Relative Risk (SIR) 95% CI 
Allardice et al. [79] 2003 1 1.7 0.04-9.26 
Chaturvedi et al. [80] 2009 192 5.6 4.8-6.5 
Clifford et al. [81] 2005 6 8.0 2.9-17.4 
Dal Maso et al. [82] 2003 18 21.8 12.9-34.6 
Engels et al. [83] 2008 28 2.9 1.9-4.2 
Engels et al. [84] (1) 2006 10 7.7 3.7-14.1 
Engels et al. [84] (2)                  2006 34 4.2 1.8-3.1 
Engels et al. [84] (3)               2006 30 5.3 3.6-7.6 
Newnham et al. [85] 2005 3 1.0 0.2-2.9 
Schulz et al. [75] 2009 6 studies 5.82 2.96-11.3 
Serraino et al. [69] 2007 22 14.6 9.1-22 
Srisawat et al. [70] 2008 2 789.83 88.76-2851 
 
Studies from Africa have not demonstrated a similar marked increased of relative risk of cervical 
carcinoma as a result of HIV, as detailed in the table below [4-7, 86, 87], although the risk of pre-
neoplastic lesions have been reported to be high in some studies [88-91].   
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Table 2.4 Relative Risk (OR) of cervical carcinoma associated with HIV from some African 
studies. 
Author [ref] Year No cases Relative Risk(OR) 95% CI 
Holmes et al. [86] (HIV1/2) 2009 149 6.5 2.1-19.8 
Holmes et al. [86] (HIV1) 2009 149 8.2 1.3-50.0 
Holmes et al. [86] (HIV2) 2009 149 5.3 1.3-21.4 
Kahesa et al. [87] 2008 138 2.9 1.4-5.9 
Newton et al. [6] 2001 65 1.6 0.7-3.6 
Schmauz et al. [4] 1989 34 0.23 0.05-0.96 
Sekirime et al. [7] 2007 116 1.26 0.45-3.49 
Sitas et al. [92] 2000 1323 1.6 1.1-2.3 
Stein et al. [93] 2008 1586 1.6 1.3-2.0 
Ter Muelen et al. [5] 1991 50 0.96, p-value 0.03 Not given 
 
  
2.11 HPV PERSISTENCE AND HIV 
 
HPV persistence as a consequence of HIV infection could be attributed to a number of 
mechanisms. HIV has been known to turn the cervical milieu to a more favourable for HPV 
persistence [94]. Persistence could also be due to dysregulation of local cervical humoral immunity 
as a consequence of HIV infection [95].    
This apparent discrepancy is difficult to explain, but a lack of early detection and screening 
programs, and the relatively short life expectancy are possible explanations. Thus, a significant 
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percentage of cervical cancers in HIV-positive women in Sub-Saharan Africa could not have been 
detected before their deaths. 
 
2.12 NATURAL HISTORY OF HPV INFECTION 
 
HPV-induced cervical cancer is a multi-step process. HPV DNA in the cervix uteri is frequently 
detected in women at all ages, most frequently among young women soon after the start of having 
sexual intercourse. However, in the majority of the women, HPV infection does not lead to a 
clinical manifestation and is cleared by the host immune system in a relatively short time (6-12 
months) [72, 96, 97]. In a small percentage, HPV infection becomes persistent and induces the 
development of low- and/or high-grade cervical intraepithelial neoplasias (CIN), which can still 
regress or progress to an invasive cervical carcinoma after a period of latency. These lesions are 
usually localized, although why they remain sharply demarcated is not clearly understood [98]. 
Factors important for the progression to cervical carcinoma are the virulent properties of the virus 
and the ability to evade the immune system.  
 
2.13 STUDIES ON CERVICAL CARCINOMA DONE IN UGANDA 
 
One of the first studies on HIV and cervical carcinoma was done at the beginning of the AIDS 
epidemic by Schmauz et al. [4]. However, the sample size was too small (50 controls and 34 cancer 
patients only) to reach any definite conclusions. Two other studies done later found no association 
of HIV and cervical carcinoma [6, 7]. These two studies did not assess the possible role of HPV. A 
study on the risk of cervical carcinoma as a consequence of HPV was done by Newton et al based 
on HPV serology only [8]. The relative risk of cervical cancer was associated with a higher level of 
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HPV antibodies. Some recent studies have focused on the prevalence of HPV types in women 
without cervical carcinoma. One study only included adolescents [99] , while the other two studies 
were in women up to the age of 49 [100] and 51 [101] years respectively. These studies found a 
high prevalence of HPV in the women. An earlier study on HPV variants in genital cancers [102], 
found HPV 16 Af1 sequences in 100% of tumour tissue and in 6.25% of scrapes. The authors 
concluded that progression to cancer is mainly associated with the HPV 16 Af1 variant. 
From the foregoing, it becomes apparent that there are some gaps in knowledge about HPV and 
subsequent events in cervical carcinoma. For example what are the types of HPV in cervical 
carcinomas, and how does the presence of HPV DNA affect the biological behaviour of tumours.  
Does immunosuppression increase the risk of HPV associated cervical carcinoma? 
Apart from the studies from this thesis, many previous studies have not adequately addressed these 
gaps. The characterization of the HPV spectrum and the interaction of HPV with HIV in the 
Ugandan population would provide important background information for the development and 
evaluation of future HPV vaccines.  
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3 AIMS OF THE THESIS 
 
This thesis addresses some aspects of invasive cervical carcinoma in Uganda. The main aims are:  
 
1.  To ascertain the types of HPV distribution in invasive cervical cancer in Uganda. 
 
2.  To ascertain the usefulness of immunohistochemistry profiles in tissue microarrays in archived 
samples of  adenocarcinoma of the uterine cervix that had been tested for HPV DNA, and in 
particular to assess if it would be possible to define the tissue of origin of HPV negative 
adenocarcinoma samples. 
 
3. To estimate the relative risk of cervical carcinoma in association with different HPV types and  
HIV in Kampala, Uganda. 
 
4. To compare HPV detection in fresh and paraffin embedded cervical carcinoma specimens. 
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4 MATERIALS AND METHODS 
 
4.1 STUDY SITE 
 
4.1.1 Studies reported in papers I and II 
The study was conducted at the Department of Pathology, Makerere University. This 
department receives biopsy specimens from most hospitals in Uganda. Until the early nineties, 
the department was the only laboratory offering diagnostic histopathology services in Uganda. 
186 cases of histologically diagnosed cervical carcinomas were obtained from the archives. The 
tissues were re-embedded in fresh paraffin wax and sectioned at four micrometer thickness. The 
first sections were stained with heamatoxylin and eosin (H&E) to confirm the diagnosis and 
also suitability of sample for HPV testing. Subsequent sections were the put in proteinase K for 
polymerase chain reaction. A third section was obtained to re-confirm the presence of tumour in 
the sections taken for PCR. For paper II, 26 cases of adenocarcinoma with known HPV status 
were stained with a panel of antibodies, namely, p16, eostrogen, progesterone, vimentin and 
carcinoembryonic antigen. 
 
4.1.2 Studies reported in papers III and IV  
The study was conducted in Mulago Hospital, which is the national referral and teaching 
hospital for the Faculty of Medicine, Makerere University, Kampala, Uganda. The 
Gynaecological Unit has three wards on the fifth floor viz. 5A, 5B and 5C. Each ward has 40 
beds for gynaecological patients. The Unit has an emergency gynaecological section on ward 
5A and runs three gynaecological clinics per week. Gynaecological cases are admitted through 
the gynaecological clinics or the emergency section on ward 5A. On average, each clinic attends 
to about 150 patients and admits about 10 cases with cervical cancer per month. Patients 
attending the Gynaecological clinics or emergency section are residents of Kampala City with a 
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population of about 1,000,000 and the surrounding areas. A few cases are referred by medical 
practitioners, although most come directly. 
 
4.2 STUDY SUBJECTS 
 
Patients eligible for the study included all women consecutively diagnosed with incident 
invasive cervical carcinoma who present to Mulago Hospital, Kampala, and gave their consent 
to participate in the study during the period September 2004 and December 2006. Cases were 
recruited from among women admitted to the gynaecological unit, and had a histologically 
confirmed diagnosis of cervical cancer.  
Inclusion criteria: 
      - incident cases who have not yet undergone primary treatment for cervical cancer 
      - resident of Uganda for at least two years 
      - aged 18 to 74 years 
      - ability to give informed consent 
      - willing to provide samples 
Exclusion criteria: 
     - incident cases who had already undergone primary treatment for cervical cancer 
      - resident of Uganda for less than two years 
      - aged less than 18 or more than 74 years 
      - inability to give informed consent 
      - not willing to give samples 
      - those terminally ill      
 
Patients were excluded if tissue and blood samples could not be collected because they were in 
poor health or for any other reason that might interfere with established patterns of patient care. 
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A log form was kept throughout the study period. All potential participants in the study were 
recorded, and for non-participants, the reasons were also be recorded (e.g., refusal, terminal 
patient, etc.). 
 
The goal of enrolling all consecutive patients was aimed at reducing bias that would occur if 
any criteria were used to select cases, for example stage, duration of symptoms, tribe, etc. 
Control women were recruited from among women accompanying or visiting cervical cancer 
patients. 
Inclusion criteria: 
      - resident of Uganda for at least two years 
      - aged 18 to 74 years 
      - ability to give informed consent 
      - willing to provide samples 
Exclusion criteria: 
      - resident of Uganda for less than two years 
      - aged less than 18 or more than 74 years 
      - inability to give informed consent 
      - not willing to provide samples 
 
 In Uganda, all hospitalised patients have with them one or more accompanying persons who 
are responsible for preparing food and taking care of the basic needs of the patients. These 
accompanying persons are in general women members of the same family or clan, having or 
not direct family blood links with the patient. We first invited women who were closest in age 
to the case patient. Since we did not intend to do individual matching of cases and controls, 
but only frequency matching by 5-years age groups, more than one control woman 
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accompanying a cancer case were sometimes included in the study. This allowed for 
compensation for refusals or unavailability of suitable accompanying women among certain 
cancer patients.  
The motivation of enrolling visitors to the cancer patient was to assure the inclusion of control 
women who live in the same areas of the country as cancer cases. This was necessary, as the 
prevalence of HIV in Uganda varies broadly from one area to another.   
Control women were offered visual inspection of the cervix uteri and a Pap smear test. Women 
diagnosed with pre-malignant and malignant cervical abnormalities were referred for standard 
treatment at the Mulago Hospital. Results from the Pap smear test were made available quickly 
enough to allow women to get the Pap smear result before leaving the hospital (i.e., during the 
case patient period of hospitalization). The gynaecologist examining control women offered 
appropriate antibiotic treatment to those with a syndromic diagnosis of cervical and vaginal 
infections.    
  
The study subjects for articles IV consisted only of cancer cases which were analyzed at both 
DDL and ICO. The recruitment details are shown in the flow chart below.  
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Cases and controls samples are tested for 
HPV and HIV analysis (paper 3) 
HPV+
317 (222 Cases, 95 Controls)
HPV-
231 (17 Cases, 214 Controls)
548 (239 Cases, 309 Controls)
HPV testing
Combined HPV and HIV 
525 (222 Cases, 303 Controls)
HIV+
109 (55 Cases, 54 Controls)
480 (226 Cases 254 Controls)
HIV -
HIV testing
589 (281 Cases, 308 Controls)
 
 
4.3 DATA COLLECTION PROCEDURES 
 
The data were collected using questionnaires and laboratory tests. The details of how the cases 
and controls were enrolled and the number tested for HPV are shown in the flow chart above. 
 
4.3.1 Questionnaires 
All the study subjects were administered standard questionnaires asking for information about 
social status, reproductive history parity, age at first child birth, number of abortions, lifestyle, 
alcohol consumption, smoking, sexual practices, contraceptive use, age at first intercourse, 
number of lifetime sexual partners, history of sexually transmitted diseases and their 
frequencies and demographic details age, educational status, marital status and economic status 
including sources of income. 
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4.3.2 Collection of biological samples  
Tumour samples were obtained from patients with cervical carcinoma, and exfoliated cervical 
cell samples were obtained from control women using cervical brushes. 
Among women with invasive cervical carcinoma, biopsies of the cervical lesions were collected 
under general anesthesia. Samples were immediately stored into sterile specimen tubes and 
transported in a flask containing ice to the pathology laboratory. There the specimen was 
divided into two parts: one part was fixed in 10% buffered formalin (for 12 to 24 hours) for 
histological processing and diagnosis, and the other half was kept in a Nuc tube, labeled and 
stored at -80oC until shipped for HPV analysis. In case the tissue was deemed to be very small, 
the whole tissue was processed for histological diagnosis. The biopsy samples were processed 
using the automatic tissue processor. They were paraffin embedded, sectioned at 4 µm thickness 
and stained with Haematoxylin and Eosin.  
Among control women, exfoliated cervical cells were collected before any treatment with two 
Cervex brushes. The first brush was rinsed in PreservCyt solution (ThinPrep, Cytyc 
Corporation) according to the manufacturer’s instructions and kept at room temperature until 
shipped to the laboratory for HPV testing. The second brush was used to make a smear and 
stained with Pap stain; smears were classified as normal or abnormal.   
 
4.3.3 Laboratory tests 
4.3.3.1 T cell counts 
This was done using flow cytometry with the Bectondickinson automatic FACS count 
instrument. In addition to CD4 counts, it also gives the CD8 count and CD4:CD8 ratio. The 
analysis was done at Ebenezer Clinical Laboratory in Kampala (South African National 
Accreditation System Laboratory No. M0221, ISO 15189, International Organization for 
Standardization). 
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4.3.3.2 HIV test 
The analysis was done at Ebenezer Clinical Laboratory in Kampala. HIV testing was offered to 
cases and controls. In case a woman manifested interest in knowing the result of the HIV test, 
pre- and post-test counseling were offered, according to a consolidate methodology available at 
the Mulago Hospital. Routine HIV testing and counseling has been found to be highly 
acceptable in Ugandan hospitals [103]. 
This was done using rapid tests as recommended by Downing et al. [104]. Briefly, blood was 
initially tested by the Capillus method (Capillus HIV-1/HIV-2 (CP) Trinity Biotech, Galway, 
Ireland). Negative results were reported as negative, and no other confirmatory tests were done. 
For positive results, a confirmatory test using the Serocard (Trinity Biotech, Galway, Ireland) 
was performed. 
When the results from the Serocard were positive, the results were reported as positive. 
However, if the results from the Serocard were negative, a tiebreaker test using the Multispot 
test (Bio-Rad Laboratories) was done, and the result reported as negative or positive. The tests 
were done according to the manufacturer’s instructions. HIV was assessed as positive (exposed) 
or negative (not exposed).  
4.3.3.3 HPV tests   
All paraffin embedded samples were stored and transferred to the HPV testing laboratory at 
ambient temperature. The fresh specimens were stored at -80°C and transferred to the HPV 
laboratory using dry ice. 
Proteinase K (Sigma) digestion for 16 hours at 56°C temperature was used to obtain a tissue 
lysate containing DNA from the paraffin inner 5 µm sections. SPF10 PCR was performed using 
10 µl of a 1:10 dilution with water of the tissue digest in a final reaction volume of 50 µl [14]. 
The amplified PCR products were tested using a probe hybridization with a cocktail of 
conservative probes recognizing at least 54 mucosal HPV genotypes in a microtitre plate format 
for the detection of HPV DNA. Optical densities (OD450) were read on a microtitre plate 
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reader. HPV DNA positive samples were subsequently analysed by HPV SPF10-LIPA25 
(version 1: produced at Labo Biomedical Products, Rijswijk, The Netherlands) [14], a reverse 
hybridization technique that detects 25 high-risk and low-risk HPV types (6, 11, 16, 18, 31, 33, 
34, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 66, 68/73, 70, 74). The sequence 
variation within the SPF10 primers allows the recognition of these different HPV genotypes, 
except for the types 68 and 73, as their interprimer regions are identical and cannot be 
distinguished on this test. After PCR, 10 µl of the amplimers was used to perform reverse 
hybridization for HPV genotype identification. The positive hybridization on the strips is 
visualized as a purple band by means of a precipitating colour substrate on the probe site. 
Specimens that were HPV/DNA positive but did not hybridize with any of the 25 probes were 
coded as HPV type X (unknown type). Amplification of a fragment of the human β-globin gene 
was performed in all HPV/DNA negative samples to assess DNA quality. HPV type specific 
distributions were calculated among HPV positive women. All SPF10-LIPA25 PCR detection 
and typing was performed at the facilities of DDL Diagnostic Laboratories (DDL, Voorburg, 
Netherlands) and at Institut Català d'Oncologia (ICO, Barcelona).  
4.3.3.4 Tissue Microarrays 
Tissue Microarrays (TMA): Three punches (gauge 1mm) of pre-existing paraffin embedded 
tissues were obtained from each block and then re-embedded in an arrayed master block using 
the manual tissue microarrayer (Beecher Instruments, Silver Spring MD). The punch specimens 
were performed in the most representative areas of the tumours, discarding necrosis or artifacts. 
Four micron paraffin sections were cut from the TMA blocks and deparaffinised through 
alcohols and xylene before immunostaining.  
4.3.3.5  Immunohistochemistry 
Immunohistochemistry (IHC): Monoclonal antibodies included: CEA (clone B0194- 
11M-P, BioGenex), p16 INK4a, p16 (clone JC8, Biocare Medical), Vimentin (clone V9, Dako), 
estrogen receptor alpha, ER (clone 1D5, Dako), progesterone receptor, PR (clone PgR 636, 
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Dako). The tissue sections were pre-treated for antigen retrieval, and the Dako Autostainer 
universal staining system was used with the EnVision+ Dual Link System-HRP, a two-step IHC 
staining technique. This system is based on an HRP labelled polymer, which is conjugated with 
secondary antibodies.  
The final reaction was done with diaminobenzydine and slides were counterstained with 
hematoxylin. The immunohistochemical stains were interpreted by one of the authors (BL) and 
the results were reported as positive or negative using the following criteria for each antibody. 
ER and PR were considered positive when more than 10% of the tumour cells displayed nuclear 
positive staining. p16 was considered positive/overexpressed if more than 75% of the tumour 
cells showed cytoplasmic and/or nuclear staining. CEA was considered as positive if more than 
10% of the neoplastic cells showed cytoplasmic positive staining, and vimentin was considered 
positive only when more than 20% of the tumour cells displayed cytoplasmic staining. The 
cutoff points for most of the antibodies were those used for routine diagnosis at Barcelona, 
while the cutoff point of 75% for p16 was chosen because this cutoff point is both sensitive and 
specific for HPV related adenocarcinoma [105]. 
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5 STATISTICAL ANALYSIS 
 
5.1 ARTICLE I  
 
Chi square statistics was used to detect differences categorical data.  
 
5.2 ARTICLE II 
 
The chi-square test was used to determine significant differences between HPV positive and 
HPV negative adenocarcinomas and expression of, p16, CEA, ER, PR and vimentin.  
 
5.3 ARTICLE III 
 
The Odds ratios (OR) and associated 95% confidence intervals (CI) were calculated using 
logistic regression models. We fitted age-adjusted models for each HPV type or groups of HPV 
types, as well as models also adjusting for HIV (positive or negative) and CD4 counts reduction 
per 100 cells, as a linear continuous variable. For cases where it was not possible to estimate the 
lower or upper limit of 95% CI, only one limit was estimated [106].  
 
5.4 ARTICLE IV 
 
The Kappa statistics and McNemar test were used to test the statistical significance of HPV 
detection between fresh samples and paraffin blocks, while the Chi square test was used to test 
the statistical significance of HPV detection between SCC and ADC in both fresh and paraffin 
blocks. Where appropriate, 95% confidence intervals were computed and the level of the 
statistical significance test was 0.05. 
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6 ETHICAL ISSUES 
 
Permission to carry out research was obtained from the Research and Ethical Committee of the 
Faculty of Medicine and the Uganda National Council of Science and Technology. For studies 
3 and 4, written informed consents were obtained from all participants.  
The potential participant was informed about the study in the local language. She was explicitly 
given the opportunity to ask questions and discuss in more detail any concerns she may have 
had. If she accepted, she was then asked to sign a written, informed consent appropriately 
translated and read to her in the local language, accepting the objective, procedures, and 
constraints and benefits of the study. 
Hospitalized patients are not routinely tested for HIV in Uganda, basically due to lack of 
resources for testing and treatment. Thus, the HIV testing and CD4 counting were done for 
study purposes only. During the pre HIV testing counseling, the women were told about 
causation and complications of AIDS. During the post-counseling sessions, the women were 
given explanations on how to live safely, and the availability of treatment options for those who 
were positive. In cases deemed necessary, referral to relevant health care providers were done 
for control women. Therefore, case patients and control women were asked in a private section 
with a specialized HIV counselor if they:  
a) agreed to donate blood sample for study purposes,  
b) agreed to having the blood tested for HIV,  
c) if yes, if they wanted to know the results or not, 
d) women willing to know the results of their HIV test had an appointment booked in advance 
with the HIV counselor working in the study team. The date was booked while the case 
patient was hospitalized, thus allowing both the case patients and control women access to 
information without extra trips to the hospital.   
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Results from the Pap smear test were made available quickly enough to allow the women to get 
the results before leaving the hospital (i.e. during the case patient period of hospitalization). All 
control women diagnosed with pre-malignant and malignant cervical abnormalities were 
referred for standard treatment at the Mulago Hospital.  
Strict confidentiality was followed at all times, and no information was made public. All 
specimens were labeled with unique identification numbers and the corresponding names and 
document kept by the investigator in a locked cabinet.  
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7 SUMMARY AND DISCUSSION OF THE STUDIES’ 
RESULTS 
 
7.1 PAPER I 
 
Of the 191 FFPE tissue blocks, each corresponding to a case of cervical cancer, five were 
excluded due to extensive necrosis of the samples on histological review, leaving 186 cases for 
HPV analysis. 146 were SCC, 35 were ADC, three were adenosquamous carcinoma, and two 
were undifferentiated carcinoma. 114 tested positive for HPV and 72 tested negative for HPV. 
Of the HPV positive cases, specific HPV types were identifiable in 109 while in the remaining 
five, no specific HPV could be identified (HPVX). HPV specific types identified were16, 18, 
31, 35, 39, 44, 45, 51, 52 and 70. These occurred as single infections in 105 cases, double 
infections in three cases and triple infections in one case. HPV 16 was the most prevalent in 
SCC (47.8%), while in ADC HPV 18 was the most prevalent (50%). 
A high proportion of cervical carcinoma tested from archival FFPE specimens harboured HPV, 
with more than 70% of the positive cases being HPV 16 or 18.  
Our prevalence rate of 59% is somewhat lower, but is higher than that found in cervical cancer 
cases from Mauritius [107]. However, our overall prevalence of the two major HPV types (16 
and 18) was 75%, which is similar to the recent world study by Castellsague et al. [22] and from 
Algeria [108] and the results from Scotland [109]. Similar low detection rates of HPV in 
archival cervical tissue have been reported recently from Norway [110]. Further, our negativity 
rates could also attributed to a very high percentage of necrosis in some of the paraffin 
embedded tissue and also among samples that were collected before the 90s. Formalin fixation 
has been shown to affect DNA [111]. 
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The results of the study by Castellsague et al. [22], which pooled data of eight case control 
studies conducted in North Africa (Algeria, Morocco), South America (Brazil,  Paraguay, Peru) 
and South East Asia (India, Thailand, Philippines), showed HPV 16 prevalence of 52.1%, HPV 
18 at 39% and HPV 45 6.2%. However, regional differences were noticeable with a high 
prevalence of HPV 16 in North Africa and South America, while in South East Asia, there was 
a high prevalence of HPV 18. In this study, the prevalence of HPV 16 is rather low, while the 
HPV 18 prevalence is much higher than those from North Africa and South America. 
 
In the study of Bosch et al. [17], HPV 16 occurred in 58.8% and 52% of squamous carcinomas 
and adenocarcinomas respectively, while the prevalence of HPV 18 was 39% in 
adenocarcinomas and 18% in squamous carcinomas. Our data shows a lower prevalence of 
HPV 16 in both squamous and adenocarcinomas, but a higher prevalence of HPV 18 in both 
tumours. We also did not observe types 31, 39 and 52 in adenocarcinomas, suggesting that these 
types may not be associated with a risk of adenocarcinomas, which is in accordance with 
previously reported data [17, 26]. The absence of these types was also found by other 
investigators [27, 108].  
 
7.2 PAPER II 
 
Twenty six (26) cases of cervical adenocarcinoma, which had been tested for the presence of 
HPV DNA were subjected to immunohistochemistry with p16, CEA, vimentin, ER and PR. 13 
of these were negative for HPV. Over-expression of p16 was observed in 15 of 26 ADC. Of the 
cases that were p16 positive, eight were HPV positive, while the remaining seven were HPV 
negative. CEA was positive in 12 of 25 cases. Among the CEA positive cases, seven were HPV 
positive, and five were HPV negative. All five CEA positive and HPV negative cases had 
histological features of endocervical ADC, suggesting an endocervical origin. Vimentin 
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expression was positive in 6 out of 26 ADC, three of which were HPV positive and the other 
three HPV negative. Of the three HPV negative and vimentin positive ADC, one had a 
mucinous endocervical pattern, and the other two were of nonspecific features, most likely of 
endometrial origin. ER was not detected in any of the samples, while PR was positive in two 
cases, both HPV positive. These two are most likely of endocervical origin. The other five cases 
which were negative for all the markers, two had features of endocervical origin, and two others 
had features suggestive of endometrial origin, while the remaining one had nonspecific features. 
The expression of the different antibodies did not differ between the HPV positive and HPV 
negative cases.    
The results showed that use of immunohistochemisrty in differentiating HPV negative cervical 
adenocarcinoma appears nonspecific, but some may be of value. 
Compared with RIS TT study, which used similar HPV testing methods [112], the HPV positive 
rate in these series of ADC is low. The low detection rate could be due to denatured DNA by 
formalin fixation [111]. With regard to p16, only 57% of our cases were positive, suggesting 
some of the cases may not be of cervical origin. Some of these p16 negative ADC could be of 
endometrial origin. However, p16 cannot be considered as an ideal marker for HPV, although 
some authors suggest that it is more sensitive than ISH [113]. Moreover, cases of p16 positivity 
has been reported in some HPV negative ADC, suggesting HPV independent mechanisms of 
p16 over-expression as reported for Bowen’s disease [45, 114]. Some endometrial carcinomas 
have also been found to express p16. Among the 13 HPV negative ADC, expression of CEA 
indicated they are more of cervical origin. Besides, CEA has been suggested as a marker of 
reserve cells [115]. Cervical carcinoma arising from reserve cells are usually HPV positive, 
while those from cervical epithelium are HPV negative [115]. The HPV status could be 
explained by the fact that there are two types of cervical ADC, one arising from reserve cells, 
and the other arising from endocervical epithelium. This is supported by the findings of Smedts 
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et al. [116], who found two phenotypically distinct types of AIS, that is AIS with a reserve cell 
marker phenotype and AIS with an endocervical glandular phenotype. 
 
7.3 PAPER III  
 
The study included 316 cases of invasive cervical carcinoma and 314 controls. HPV tests were 
done in 255 cases and 309 controls, while HIV testing was done in 293 cases and 308 controls. 
Of the 255 cases and 309 controls, HPV genotypes were detected in 222 cases (87.1%) and 95 
controls (30.1%). HIV tests were positive in 55 cases (18.8%) and 54 controls (17.5%). 
For SCC, the relative risk was statistically significantly increased for any HPV positive, high 
risk HPV types, HPV 18 related types, HPV 16 related types and some specific high risk HPV 
types as assessed by age-adjusted OR. The OR for any HPV positive  (50.8, 95% CI: 25.8-
113.9), single infections (33.3, 95% CI: 20.2-56.7), HPV 16-related types (11.6, 95% CI: 7.5-
18.5), HPV 18-related types (9.4, 95% CI: 5.3-17.4), and high-risk types (64.5, 95% CI: 35.4-
126.6), in particular HPV 16 (29.1, 95% CI: 15.4-60.7), HPV 18 (9.6, 95% CI: 4.6-22.3) and 
HPV 45 (58.7, 95% CI: lower limit >7.9). 
The OR for ADC were statistically significantly increased for any HPV positive (12.9, 95% CI: 
5.0-41.8), single HPV infections (13.7, 95% CI: 6.0-34.0), HPV 16-related (3.6, 95% CI: 1.5-
8.2), HPV 18-related infections (22.8, 95% CI: 9.3-58.9), high-risk HPV infections, in particular 
HPV 16 (11.6, 95% CI: 4.3-31.8), HPV 18 (18.5, 95% CI: 6.6-54.4) and HPV 45 (297, 95% CI: 
lower limit >26.4).      
 Multiple infections and infections with low-risk HPV were not associated with increased ORs 
for both SSC and ADC. Adjustment for HIV as well as CD4 count decline did not change the 
OR estimates substantially with the different HPV types.  
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Overall, there was no effect on the relative risk of SCC with regards to most HPV types. HIV 
associated ORs for SCC were statistically significantly increased for low-risk HPV and multiple 
HPV infections.  
Analysis of HPV relative risk in subgroups of HIV negative and HIV positive showed as having 
a statistically significantly increased OR for most HPV types, with the exception of HPV 18-
types, which were only associated with an increased risk in HIV negative.       
The results showed high relative risk of both squamous cell carcinoma and adenocarcinoma of 
the cervix with HPV 16 and 18, and moderate relative risk with HPV 45. Concurrent infection 
with HIV did not increase the relative risk with these three HPV types, but was associated with 
statistically borderline increased relative risk of squamous cervical carcinoma only with low-
risk types and multiple infections with HPV types.  
 
The HPV types associated with both SCC and adenocarcinoma risk in our study has also been 
found to be associated with the most invasive cervical carcinoma in other regions of the World 
[26, 117]. The relative risks also varied in the two histological types, namely SCC and 
adenocarcinomas. As in some previous studies, we also found HPV 16 predominating in SCC 
and HPV 18 in adenocarcinomas [118], although de Cremoux found that up to one third of 
cervical carcinomas were not associated with HPV 16 or 18 [119]. 
The high OR for SCC associated with HPV 16 in our study is similar to that reported by Chen et 
al. [120]. In addition to HPV 16, they also found an increased OR for SCC associated with HPV 
52 (OR 3.04, 95% CI: 1.42-6.47) and HPV 58 (OR 5.22, 95% CI: 2.07-13.19), which was not 
the case in our study. Another exceptional finding was from Mexico, in which the OR for HPV 
18 was higher than that of HPV 16 [23], although a similarly high OR for SCC associated with 
HPV 18 had been reported previously [121-123]. Some authors have found low-risk HPV in 
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SCC [21, 124]. For adenocarcinomas, the OR for HPV 18 in our study was lower than that 
reported by in a pooled case-control study by Castellsagué et al. [22]. 
The different relative risks of cervical carcinoma associated with HPV in many studies could be 
due to differences in HPV prevalence [17], which may affect risk [125]. Another possible 
explanation is that there are differences in the pathogenesis of the two major types of cervical 
carcinoma [126]. Studies by Smith et al and Madeleine et al found increased risk of SCC 
associated with trichomonas, but no increased risk of adenocarcinoma. Another possible factor 
is smoking [127], although this is unlikely in Uganda, where the prevalence of smoking is very 
low [128, 129]. The low relative risk of cervical carcinoma with other high-risk HPV types is 
supported by the low prevalence of these types in cervical carcinoma from various studies [17, 
130]. 
Although many studies have shown increased risk of cervical carcinoma as a result of HIV 
infection [87, 131, 132], some have found low relative risk [90, 133]. Of interest was a lack of 
association between HIV and cervical cancer in general. After adjusting for HPV infections, the 
association between HIV and SCC was not statistically significant with most HPV types, except 
low-risk HPV and multiple HPV infections. For adenocarcinoma, there was no association.  
Our study did not corroborate the hypothesis that HIV infection increases a woman’s risk for 
invasive cervical carcinoma. The OR associated with different HPV infections were similar in 
both HIV positive and negative women, except for low-risk HPV and multiple infections for 
SCC. This could be attributed to impaired immunity as previously suggested [134, 135].   
 
7.4 PAPER IV 
 
Overall, more than 80% of both fresh and formalin fixed tissues were positive for HPV, giving 
and overall agreement in HPV detection in both specimens at 86%, which is statistically 
significant. In both types of specimens, single infections were predominant, with HPV 16 
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accounting for 47% in both specimens and almost identical proportions of HPV 33, 52 and 58, 
while the proportions of the other HPV types were different. When analyzed for overall 
agreement, complete agreement was found to be 59.7%, partial agreement 5.3% and complete 
disagreement 35.0%. Comparing HPV detection by histological type of cervical carcinoma, 
adenocarcinomas were more likely to be HPV negative than squamous cell carcinoma in both 
fresh and fixed tissue. 
 
The results of our study showed comparable HPV detection in both fresh and FFPE tissue by 
SPF10 LiPA method. Some previous studies that compared the paraffin embedded tissues with 
exfoliated cells or cervical scrapes and not frozen specimens found high agreement [136-138]. 
However, these were cases of pre-neoplastic lesions, not invasive cervical carcinoma. A 
comparison of cervical scrapes and FFPE tissues from invasive cervical carcinoma cases found 
very high HPV type specific concordance [139]. The SPF10 which we used is more sensitive, 
but less specific than the GP5 and GP6 method [140]. Other previous studies also found low 
HPV DNA prevalence in ADC of the cervix [25, 141, 142], the low detection being attributed to 
low viral load, fewer episomal copies or loss of viral genome during integration in cervical 
adenocarcinoma as suggested by Park [143]. 
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8 GENERAL DISSCUSSION  
 
 
The findings of this thesis have highlighted various aspects of cervical carcinoma in Uganda. 
One of the areas is HPV types associated with cervical carcinoma in Uganda. The results show 
that the current vaccine maybe able to prevent a high proportion of cervical carcinoma in 
Uganda. This is consistent with findings of studies from other previous investigators [17, 22, 
108]. Besides, our results show that HPV types associated with cervical carcinoma appear to be 
stable over the years. This suggests that the current available vaccines could probably be of use 
for many years ahead, substantially diminishing the cervical cancer impact in the country. 
Another aspect was on the risk of cervical carcinoma associated with HPV. The relative risks 
were particularly high with HPV 16, 18 and 45. This is similar to results of some previous 
studies [26, 117], but also differs from those reported from some areas like Mexico [23] and 
Taiwan [120]. The implication of results from this thesis suggest that in Uganda, women who 
are positive for HPV 16,18 or 45 may need more frequent screening compared to those with 
other high-risk HPV. The results of this thesis also highlight the fact that there are variations in 
relative risks of cervical carcinoma, suggesting possible oncogenic differences of HPV isolates 
from different areas or differences in regional cofactors of cervical carcinoma. 
One of the factors that have affected cervical carcinoma risk has been the AIDS epidemic. 
Several studies have shown an increased relative risk of cervical carcinoma as a consequence of 
HIV infection [87, 131, 132], although others indicated no increased risk [90, 133].  However, 
our study did not corroborate the hypothesis that HIV infection would increase a woman’s risk 
for invasive cervical cancer, and the OR associated with different HPV infections and cervical 
cancer risk were similar in HIV positive and negative women, except for low-risk and multiple 
infections for SCC. Our findings have shown that in the setting of HIV, SCC and not 
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adenocarcinoma is likely to arise as a consequence of some HPV types. Other studies need to be 
done to elaborate on these aspects. 
This has implications with regard to cervical carcinoma screening in HIV positive women, 
especially those born with HIV. In addition, it suggests that ADC may not be influenced by 
HIV infection. Although other previous studies have indicated increased relative risk of cervical 
carcinoma as a result of HIV infection in Africa [87, 132], this could be due to the fact that there 
was no adjustment for HPV. 
Further insight was also demonstrated in the use of different samples for HPV testing. While 
other investigators compared fresh tissue with cervical scrapes, we were able to compare fresh 
samples and paraffin embedded tissue from same patient. This indicates that both specimens 
gave comparable results, and suggests that FFPE tissue could be used, especially in countries 
with low income.  
Comparable detection rates of HPV in FFPE samples and fresh samples demonstrated in this 
thesis indicate that the SPF 10 method is robust. Though other investigators using FFPE tissues 
found low rates of HPV detection [107, 110], this may be attributable to denatured tissue. It is 
known that DNA extracted from FFPE tissues are usually at low concentration and fragmented 
[111, 144]. The low detection rate of HPV in adenocarcinoma from both specimens is of 
interest and deserves some comments. One plausible explanation is that adenocarcinomas are a 
heterogenous group of tumours, some not being related to HPV. This is supported by results of 
Smedts et al. [116], who showed that there are two phenotypic types of AIS. The findings also 
suggest that adenocarcinomas and SCC have different pathways of HPV associated 
carcinogenesis. 
 
In this thesis, we were also able to demonstrate that the use of different antibodies maybe useful 
in distinguishing cervical adenocarcinomas from endometrial adenocarcinomas. This is of 
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particular interest, since an increase of cervical adenocarcinomas have been reported by some 
authors of late [145, 146]. Different antibodies could be used to find out if the increase is of 
cervical or of endometrial types. Besides, it is useful to find out if these cases are related to 
HPV by used of HPV DNA and p16, as suggested by Yemelyanova et al. [147]. Use of HPV 
DNA detection could also be extended to epidemiological studies of cervical adenocarcinomas 
to minimize misclassification. Our study is unique because many cervical cancer samples were 
negative for HPV, considering that HPV is a necessary cause of cervical cancer. This is 
probably because of problems during the original fixation of tissue in Uganda.  Our working 
hypothesis was that immunohistochemical markers could be useful in distinguishing the tissue 
of origin i.e cervical or endometrial of samples initially diagnosed as adenocarcinomas (ADC) 
of the cervix that were HPV negative. The fact that the samples used were from Uganda is also 
of interest, since there are very few pathological studies on cervical carcinoma emanating from 
this country, where the prevalence of diseases is amongst the highest in the world [3]. Problems 
in classification of tumours found in the Ugandan setting are probably representative of 
problems found in several other sub-Saharan countries. 
 
8.1 METHODOLOGICAL ISSUES 
 
8.1.1 Study subjects 
The aim of the thesis was to provide more information of different aspects of cervical 
carcinoma in Kampala, Uganda. The study assessed the types of HPV in cervical carcinoma and 
the use of different antibodies to ascertain the nature of HPV negative cervical carcinoma, 
compared the detection of HPV in fresh and formalin fixed paraffin embedded tissue and finally 
estimated the risk of cervical carcinoma associated with HPV and HIV infection. Compared 
with previous studies, our study had a large sample and was carried out in an area with a high 
incidence of cervical cancer [2]. 
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The selection of study subjects was based on selected criteria. All the histological materials 
were verified as invasive cervical cancer. Women selected as cases were all histologically 
confirmed as invasive cancer, and control women were those without cervical abnormalities 
cytologically. In addition, the women were interviewed using a standard questionnaire. All 
laboratory samples were obtained and processed using standard operating procedures. 
 
8.1.2 Internal validity    
To assess internal validity, we evaluated possible bias, confounding and chance. 
8.1.2.1 Bias 
8.1.2.1.1 Selection bias 
To avoid this, we did not set any criteria for selection of samples, with all potential participants 
having an equal chance. Since this was a case-control study done at a Ministry of Health 
facility, cases of cervical carcinoma who opted to use private or non-governmental health 
facilities could lead to some selection bias. 
8.1.2.1.2 Misclassification bias 
For the case control study, we had strict guidelines on classification of exposure variables. 
Laboratory samples were processed under standard conditions with clear definition of positive 
or negative outcomes. The technical staff who did the laboratory analysis were blinded. Despite 
these measures, some misclassification could have occurred. Due to limited resources, 
classification of cervical carcinoma was based only on routine haematoxylin and eosin (H&E) 
stain, which could have led to some misclassification of some cases, especially 
adenocarcinoma. In order to avoid this, HPV DNA and immunohistochemistry using p16 and 
hormonal receptors have been applied with good results [147]. For control women, cervical 
smears were obtained and examined to ascertain the cervical condition. In addition, some cases 
of HPV might not have been detected, since the methods used utilizes only known HPV primers 
[10]. However, this may not affect the results significantly. 
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Use of HIV rapid tests might not have identified some infections. However, this would affect 
both cases and controls, and therefore may not affect the results adversely. Another limitation of 
the study was that we could not differentiate HIV into types 1 or 2, as has been done in studies 
from Senegal [24, 86, 132]. 
For diagnosis of cervical carcinoma, all were based only on routine H&E. These could have led 
to some occult mucus secreting adenocarcinoma being misclassified as SCC [148]. Besides, 
some endometrial carcinoma could have been misclassified as endocervical carcinoma since 
immunohistochemistry was not done on most cases of adenocarcinomas. 
Measurement of immunity is complex process. Depending on available resources, a number of 
measurements can be done. With limited resources, one can use CD4 as a measure of immunity. 
Although it is not precise, it has been used within a number of studies. 
8.1.2.2 Confounding 
Like most epidemiological studies, confounding has to be minimized in Article III. To minimize 
this, we adjusted for the effects of possible confounders in the analysis in the case control study. 
One of the confounders was age. We therefore fitted age-adjusted models for each HPV type or 
groups of HPV types, as well as models also adjusting for HIV (positive or negative) and CD4 
count per 100 cells, as a linear continuous variable(s).  Adjustment for HIV did not affect the 
OR with many HPV types. In addition to adjusting, we also analyzed the data in subgroups of 
HIV negative and HIV positive and found no significant differences in the OR of most HPV 
types. Immune status as assessed by CD4 counts as a possible confounder was also adjusted for 
with no significant effect on the OR. The fact that adjusting for HIV and its immune effects on 
the relative risk of cervical carcinoma with different HPV implies a central role of HPV in 
cervical carcinogenesis.  
Confounders associated with sexual lifestyles are more of a proxy marker for the acquisition of 
HPV. Studies have shown that two out of three people who have sexual intercourse with a HPV 
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positive person acquire the infection [72].We therefore thought it was not important to adjust 
for these factors. 
Some possible confounding could not be controlled, as the information was not available in our 
questionnaire. One example, is exposure to indoor air pollution caused by smoke from cooking 
fire, which has been associated with cervical carcinoma [149]. Like in most developing 
countries, the use of firewood for cooking is highly common in Uganda. However, this would 
have affected both cases and controls. Another factor is education level. However, a pooled 
analysis showed that there were no differences in HPV positivity by education level, and 
concluded that the excess of cervical cancer found in women with little education is not due to 
an excess of HPV prevalence, but rather by early events which may modify the cancer causing 
ability of HPV [150]. 
8.1.2.3 Chance  
To assess whether our results could be due to chance, we used statistical tests to evaluate this. 
We used 95% confident intervals and p-values. Results were the 95% CI included 1 or p-value 
>0.05 were considered to have occurred by chance. 
 
8.1.3 External validity 
Results in this thesis were obtained from analysis of archival materials as well as samples got 
prospectively. The samples were obtained in a hospital setting. Although the hospitals serve the 
population from whom the samples were obtained, one has to be cautious in extrapolating the 
findings to the overall population. However, we think the results give some baseline 
information and could be applicable to the population, since the prevalence of HPV in controls 
is similar to the one of women from East Africa [151]. 
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8.1.4 Limitations of laboratory methods 
The SPF10 LiPA system we used has a limited HPV detection, because its use is based on 
probes of known HPV types in detection methods [10]. 
Another limitation of the study was that we could not differentiate HIV into types 1 or 2, as has 
been done in studies from Senegal [24, 86, 132]. In addition, some antigens could have been 
denatured as a consequence of uncontrolled fixation of tissues. 
 
8.2 INTERPRETATION AND IMPLICATIONS OF FINDINGS 
 
8.2.1 Patient care 
From results of Paper 2, the use of some selected antibodies may be useful in differential 
diagnosis of cervical adenocarcinoma, especially cases with unusual morphological features. 
The use of FFPE tissue could also be used for detecting HPV in clinical settings. For example, 
if a woman has been diagnosed with preneoplastic lesions and a biopsy has been obtained, the 
FFPE could be used for HPV testing.  
With the availability of information on HPV, a number of women may wish to know their HPV 
status. Since our results show that HPV 16, 18 and 45 are associated with an unduly high-risk of 
cervical carcinoma, women who are found positive for these HPV may need more frequent 
screening.  
HPV testing could also be done in cases of head and neck carcinomas. A number of studies 
have shown that HPV positive head and neck carcinomas have better prognosis than those HPV 
negative carcinomas [152-154]. HPV testing on FFPE samples from patients with carcinoma of 
head and neck could therefore be performed to provide information on prognosis. 
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8.2.2 Public health policy  
Article I showed that HPV 16 and 18 accounted for 84% of all HPV positive cervical 
carcinoma. The use of the available HPV currently on trial could probably prevent most cases 
of cervical cancer in Uganda. Screening for cervical carcinoma could be supplemented with 
HPV testing if resources are available.  
Our results from article II show that use of antibodies may be useful in sub-classification of 
adenocarcinomas of cervical origin. Depending on available resources, some guidelines need to 
be developed so that women diagnosed with adenocarcinomas of the cervix may require 
additional investigation to exclude endometrial origin. In addition, the use of HPV tests as tools 
for screening for cervical carcinoma has to be used cautiously, since the risk of cervical 
adenocarcinoma would still be there.  
Results from Article III showed no excess risk of cervical carcinoma due to HPV 16 and 18 in 
HIV positive or negative women. In view of these results, both groups of women should have 
similar PAP checks if they are positive for HPV 16 or 18. However, HIV positive with low-risk 
HPV and multiple HPV infections may require more frequent PAP checks, since the relative 
risk of cervical carcinoma is marginally elevated in these groups. 
With the introduction and availability of HAART in Uganda, there are now a number of 
adolescents who are HIV positive. These HIV positive virgins may need special attention with 
regard to HPV. Questions which need to be addressed include whether they should be 
vaccinated with the available vaccine, and when, and how should cervical cancer screening in 
these groups be done. 
Results of article IV showing comparative similarity between formalin fixed paraffin embedded 
specimens and fresh samples also have some implications. Guidelines need to be developed on 
fixation of tissues. This is especially important since the tissues could also be used for other 
specialized laboratory tests.  
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8.2.3 Research 
Results from Article I showed more than 50% of cervical carcinomas from Uganda were due to 
HPV 16 or 18, with the remaining due to other HPV types. Although this indicates that the 
current vaccine could prevent most of these cases, the occurrence of cervical carcinomas due to 
other HPV types raises some concern. HPV types distribution has been shown to vary in 
different areas of the world [17]. In Uganda, it would be of interest to study the HPV prevalence 
in different areas. Studies from China by Chen et al. [25] showed that women with SCC aged 34 
years or less had a higher proportion of HPV 16 compared to those aged over 50 years in whom 
HPV 52, 58 and 39 were more common. The results of the study from China tend to suggest 
that some HPV types may be acquired later in life. Studies would need to be done in Uganda to 
ascertain if the prevalence of HPV types in various age groups also differs. In addition, the 
nature of uncharacterized HPV types (HPV X) requires more exploration.  
Results of Article IV showed fairly comparable results from the use of fresh and FFPE for HPV 
detection. The available FFPE tissue could be used to study a number of diseases related to 
HPV. A number of samples have been used for detecting HPV [137, 138]. Compared with 
tissue samples, exfoliated cervical cells or scrapes may be contaminated with vaginal samples 
and hence unreliable. Our study therefore adds valuable information to the small number of 
studies on the concordance of different genotyping methods for HPV detection in biological 
specimens stored under different conditions. Besides, our results suggest that more refined 
methods for HPV detection needs to be developed for cervical adenocarcinomas. Another area 
of research also requiring attention is whether HPV integration differs between cervical 
squamous cell carcinomas and adenocarcinomas. Lastly, research on HPV related diseases 
could be done using FFPE specimens. 
 
Results from Article II reaffirm that p16 could also be used as a surrogate marker for HPV in 
research of HPV related tumours. Redman et al suggested that p16 could be used to distinguish 
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between HPV related lesions and non HPV related lesions [155]. This could also be extended to 
epidemiological studies of cervical adenocarcinoma, where the use of a panel of antibodies 
would be advisable to avoid misclassification.   
In view of the increased relative risk of cervical squamous cell carcinoma associated with low-
risk HPV and multiple HPV infections associated HIV infection, more research needs to be 
done. It would be worthwhile to investigate if the risk predominantly is confined to only 
squamous cell carcinoma. Further, there is also a need to assess if there are some particular risk 
factors associated with this increase. Lastly, the lack of increased risk of cervical 
adenocarcinoma as a consequence of HIV infection needs to be investigated. 
 
8.2.4 HPV reference laboratory to be set in Uganda or in the East African 
Region 
Investigations of HPV associated diseases would probably differ from one country to another 
based on health priorities. In view of these, each country or regional countries could set a 
central laboratory unit for HPV. This central laboratory could then liaise with other well-
developed HPV laboratories for quality control and referral of some cases.    
 
8.2.5 HPV vaccination 
From results of this thesis on HPV prevalence in cervical carcinoma specimens, one could 
postulate that the current HPV vaccines may be able to eradicate about 70% of cervical cancer 
in vaccinated females. However, a sizable percentage of vaccinated women may still remain at 
risk of cervical carcinoma from the other HPV types, since cervical carcinoma have occurred in 
women who were vaccinated [156]. 
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9 CONCLUSIONS 
 
 
9.1 AIM 1: To ascertain the types of HPV distribution in invasive cervical cancer in 
Uganda. 
 
Conclusions: Our results confirm the role of HPV 16 and 18 in about 75% of cervical cancer 
in the Ugandan population and suggest that the currently available HPV vaccines against HPV 
16 and 18 could possibly prevent the majority of invasive cervical cancers in Uganda. 
 
9.2 AIM 2: To ascertain the usefulness of immunohistochemistry profiles in tissue 
microarrays in archived samples of  adenocarcinoma of the uterine cervix that had 
been tested for HPV DNA, and in particular to assess if it would be possible to 
define the tissue of origin of HPV negative adenocarcinoma sample. 
 
Conclusions: There is overlap in expression of p16, CEA and vimentin between HPV positive 
and HPV negative cervical ADC.  
Some HPV negative ADC diagnosed as cervical ADC may be of endometrial origin.  
CEA and vimentin may be of value in distinguishing HPV negative cervical tissue from 
endometrial ADC.   
 
9.3 AIM 3: To estimate the relative risk of cervical carcinoma in association with different 
HPV types and HIV in Kampala, Uganda. 
 
Conclusions: The OR for squamous cell carcinoma and adenocarcinoma of the cervix in 
Uganda were increased in women infected with HPV, in particular single HPV infections, 
infections with HPV16- and 18-related types, infections with high-risk HPV types, specifically 
with HPV16, 18 and 45.  
 55 
 
Adjustment for HIV infection as well as CD4 decline did not change the OR estimates 
substantially with the different HPV types.  
Cervical cancer was not statistically associated with HIV infection per se, and HIV positive 
women did not have a higher OR for cervical cancer in relation to most HPV types, except for 
low-risk and multiple infections in SCC. 
 
9.4 AIM 4: To compare HPV detection in fresh and paraffin embedded cervical carcinoma 
specimens. 
 
Conclusions: No differences in HPV positivity were observed between fresh tissue and paraffin 
embedded blocks globally.  
For specific types, only 59.7% of the cases had complete agreement on the HPV detection. 
Although HPV DNA detection was lower in ADC as compared to SCC, these differences were 
not statistically significant, p >0.05. 
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Abstract
Background: We conducted a study aiming to describe Human Papillomavirus (HPV) type
distribution in invasive cervical carcinoma in Uganda.
Methods: 191 archival cervical carcinoma samples diagnosed in the Department of Pathology,
Makerere University in Kampala between 1968 and 1992 were analysed using a sensitive PCR-
Reverse Hybridization Line Probe Assay.
Results: Out of the 186 cases of confirmed invasive cervical cancer in the study paraffin blocks,
114 were positive for HPV DNA. Specific HPV genotypes were identifiable in 109 cases: HPV 16,
18, 31, 35, 39, 44, 45, 51, 52 and 70. These occurred as single infections in 105 cases (96.3%) and
as multiple infections in 4 cases (3.7%). HPV 16 or 18 accounted for 80% (84/105) of cases with
single infection.
Conclusion: The results of this study confirm the role of HPV 16 and 18 in cervical cancer
pathogenesis in the Ugandan population. The results suggest that the currently available HPV
vaccines against HPV 16 and 18 could possibly prevent the majority of invasive cervical cancers in
Uganda.
Background
Clinical and epidemiological studies have clearly estab-
lished that infections by certain human papillomaviruses
(HPVs) types are causally linked to cervical cancer devel-
opment [1-5]. Among the high risk HPV types, HPV 16
and 18 are recognized as the main causes of invasive cer-
vical cancer and its precursor lesions [3]. These two viral
types were found in most cases of invasive cervical cancer
from 22 countries around the world [4]. HPV 16 tends to
predominate in squamous cell carcinomas whereas HPV
18 often predominate in adenocarcinomas [4,6-8]. Some
studies have also shown that there are geographical varia-
tions in HPV type distribution [1,4,9,10]. Finally, recent
data shows that HPV immunization offers the greatest
possibility for prevention of cervical cancer and has
become an important health priority to many govern-
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ments and health organizations worldwide. HPV vaccines
that are currently available include VLPs for HPV 16 and
18 [11,12] as well as HPV 11 and 6 [13]. However, geo-
graphical variations in HPV type distribution might influ-
ence the currently available HPV vaccine efficacy.
Compared to other continents (such as South America
and Asia), there is relatively little information about HPV
types in invasive cervical cancer in Africa. We conducted a
study aiming to characterize HPV type spectrum in the
archival specimens from cervical cancer cases from
Uganda population including cases diagnosed over 34
years.
Methods
191 samples from patients with histological diagnosis of
invasive cervical carcinoma from 1968 to 1992 were
obtained from the archives of the Department of Pathol-
ogy, Makerere University in Kampala, Uganda. These sam-
ples accounted for less than 5% of cervical carcinomas
diagnosed during the study period. Nine cases (4.7%)
were from the period of 1968 to 1969, 66 (34.6%) cases
from 1970–1979, 74 (38.7%) from 1980–1989 and 42
(22.0%) were from the period 1990–1992. Until the early
nineties, the Department of Pathology received most spec-
imens for histopathology services from all hospitals and
health facilities in the country.
Samples were received in formalin, which may not always
have been buffered. Tissue specimens were usually proc-
essed within 24 hours of their arrival to the hospital, but
for a fraction of samples transported from remote parts of
the country, longer times may have been required. Sam-
ples were selected randomly from the register of Pathol-
ogy Department starting in 1968; we oversampled of
adenocarcinomas (1:1) because of the special interest to
compare genotype distribution in the two major histolo-
gies of cervical cancer.
When at the testing laboratory, the paraffin embedded tis-
sue blocks were re-embedded in fresh paraffin wax and
four sections (sandwich method) were cut for testing
under strict conditions to avoid potential contamination.
The first and the last sections were stained with Haema-
toxylin and Eosin (H&E) to confirm diagnosis and to
ascertain the suitability of the tissue to continue for HPV
testing. The sections in-between were collected in a screw-
top Eppendorf tube for HPV testing. A tissue-free paraffin
block was cut after each study block to avoid any HPV
carry-over from block to block. A new blade was used for
each block and the microtome was cleaned with a vacuum
cleaner, Histoclear II and 70% alcohol. To further control
for possible sources of contamination, paraffin blocks
containing non HPV related lesions (appendicitis, lung
tumour, ovary, lymph node etc.) were included blindly in
the process at a ratio of 5%, and blank paraffin sections
were simultaneously tested.
Proteinase K (Sigma) digestion for 16 hours at 56°C tem-
perature was used to obtain a tissue lysate containing
DNA from the paraffin inner 5 μm sections. SPF10 PCR
was performed using 10 μl of a 1:10 dilution with water
of the tissue digest in a final reaction volume of 50 μl [14].
The amplified PCR products were tested using a probe
hybridization with a cocktail of conservative probes recog-
nizing at least 54 mucosal HPV genotypes in a microtitre
plate format for the detection of HPV DNA. Optical den-
sities (OD450) were read on a microtitre plate reader. HPV
DNA positive samples were subsequently analysed by
HPV SPF10-LIPA25 (version 1: produced at Labo Biomed-
ical Products, Rijswijk, The Netherlands) [14], a reverse
hybridization technique that detects 25 high-risk and low-
risk HPV types (6, 11, 16, 18, 31, 33, 34, 35, 39, 40, 42,
43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 66, 68/73, 70, 74).
The sequence variation within the SPF10 primers allows
the recognition of these different HPV genotypes, except
for the types 68 and 73 as their interprimer regions are
identical and cannot be distinguished on this test. After
PCR, 10 μl of the amplimers was used to perform reverse
hybridization for HPV genotype identification. The posi-
tive hybridization on the strips is visualized as a purple
band by means of a precipitating colour substrate on the
probe site. Specimens that were HPV/DNA positive but
did not hybridize with any of the 25 probes were coded as
HPV type X (unknown type). Amplification of a fragment
of the human β-globin gene was performed in all HPV/
DNA negative samples to assess DNA quality. HPV type-
specific distributions were calculated among HPV positive
women. All SPF10-LIPA25 PCR detection and typing was
performed at the facilities of DDL Diagnostic Laboratories
(DDL, Voorburg, Netherlands) and at Institut Català
d'Oncologia (ICO, Barcelona). HPV detection was evalu-
ated by histology classification (adenocarcinoma vs. squa-
mous cell carcinoma), year of diagnosis and presence of
necrosis in the tissue.
Ethical approval for the reported study was obtained from
Ethical Committee at Makerere University, Kampala,
Uganda.
Results
Of the 191 paraffin blocks corresponding each one to a
cervical cancer cases, 186 harboured invasive cervical car-
cinoma cells and, according to protocol, were considered
suitable for HPV detection. Five were excluded due to
extended necroses seen on the histological slide. 146 were
diagnosed as squamous carcinomas, 35 were adenocarci-
nomas, 3 adenosquamous and two were undifferentiated
carcinomas. Out of these, 114 were HPV positive and in
72 HPV could not be detected. All the negative samples
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tested negative for the presence of β-globin gene indicat-
ing a poor quality tissue. Table 1 shows the overall β-
globin gene and HPV positivity results according to histo-
logical types. There was no statistical differences between
histological type and overall HPV infection (Chi2 = 3.64,
p = 0.3). There was stability of genotype distribution of
HPV 16 and HPV 18 over time, taking into account histol-
ogy.
Specific HPV types were identifiable in 109 cases, while in
the remaining five cases no specific HPV types could be
identified (Type X). Ten specific HPV types: 16, 18, 31, 35,
39, 44, 45, 51, 52 and 70 were identified. These occurred
as single infections in 105 cases, double infections in
three cases and triple infections in one case. Analysis of
the HPV genotypes distribution among the HPV positive
cases showed that HPV 16 and 18 were the most frequent
types, followed in descending order by HPV 45, 31, 35,
51, 39 and 52. Table 2 shows the distribution of HPV
infections and histological types.
In single infections, type 16 occurred in 51 of the cases,
type 18 in 33 cases, type 45 in 11 cases, type 31 in four
cases, type 35 and 51 in two cases, types 39 and 52 each
in one case. The three double infections were found to be
combinations of types 16/45, 16/51 and 45/70 while the
triple infections included the HPV types16/44/52. When
the analysis was restricted to the histological types of cer-
vical carcinoma, HPV 16 was the most frequent in squa-
mous cell carcinomas (47.8% of cases) while in
adenocarcinomas, HPV 18 was the most prevalent type
(50%). Of the squamous cell carcinomas, 44 of the cases
Table 1: HPV/DNA detection by cervical cancer histological types
HPV negativea HPV positiveb Total
Squamous carcinoma 54 92 146
Adenocarcinoma 15 20 35
Adenosquamous 1 2 3
Undifferentiated carcinoma 2 0 2
Total 72 114 186
a HPV not detected. All these samples were human β-globin gene negative, and therefore inadequate for HPV determination
b All β-globin gene positive
Table 2: HPV type distribution according to histological types
HPV types Squamous carcinomas Adenocarcinomas Total
Infection with single HPV 110 (96,5%)
N (%) N (%) N (%)
HPV 16 44 (47.8) 7 (35.0) 51 (44.7)
HPV 18 21 (22.8) 10 (50.0) 33 (28.8)a
HPV 16 or 18 65 (70.6) 17 (85.0) 84 (73.7)a
HPV 31 4 (4.3) 0 4 (3.5)
HPV 35 2 (2.2) 0 2 (1.8)
HPV 39 1 (1.1) 0 1 (0.9)
HPV 45 10 (10.9) 1 (5.0) 11 (9.6)
HPV 51 1 (1.1) 1 (5.0) 2 (1.8)
HPV 52 1 (1.1) 0 1 (0.9)
Type X 4 (4.3) 1 (5) 5 (4.4)
Infection with multiple HPV 4 (3.5%)
HPV 16/45 1 (1.1) 0 1 (0.9)
HPV 16/51 1 (1.1) 0 1 (0.9)
HPV 45/70 1 (1.1) 0 1 (0.9)
HPV 16/44/52 1 (1.1) 0 1 (0.9)
Total 92 20 114a
a Includes two additional cases of adenosquamous carcinomas.
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presented with HPV type 16, 21 of the cases with type 18,
10 with type 45, four with type 31, two with type 35, three
single infections with types 39, 51, and 52, three double
infections and one triple infection. In the adenocarcino-
mas, 10 were found to have HPV type 18, 7 type 16, one
type 45, and one type 51. Concurrent CIN lesions were
seen in 18 cases with single HPV infections and one case
with multiple HPV types. No differences in HPV detection
were observed between the cases with and without pre-
neoplastic lesions (Table 3).
Discussion
This study shows that HPV/DNA was detected in 114 out
of 186 invasive cervical cancer samples, giving an overall
HPV prevalence of 61.3% of the samples. If the β-globin
gene results are taken into account, then HPV was
detected in 100% of the samples from which cellular DNA
was obtained.
Specific HPV genotypes were identified in 109 cases using
the highly sensitive SPF10 LiPA technology. Most of the
infections were due to single HPV types with only four
cases due to multiple infections. HPV 16 and 18
accounted for more than 70% of the cases, while the
remaining were due to the other HPV types, with HPV 45
constituting a major proportion. In squamous cell carci-
nomas, single infections due to HPV 16 and 18 occurred
in 70% of cases, while in adenocarcinomas these two
types occurred in 85% of cases. Of particular note is the
high proportion of squamous cell carcinomas (10.9%)
due to HPV 45. Almost all infections were high risk HPV
types, with exception of two low risk HPV (44 and 70)
which were seen as part of multiple infections. There were
only 5 samples classified as HPV X (HPV/DNA positive
and genotype negative); we hope to be able to genotype
these samples in the future. HPV 16 and 18 were the 2
most common types identified throughout the study
period indicating viral genotype stability in an era in
which HIV started to emerge.
The prevalence of HPV DNA in cervical cancer varies in
many studies, with some investigators reporting almost
100% [2,4]. This is probably attributable to the efficient
extraction of intact DNA from the fresh cervical scrapes or
cervical tissues used in these studies. The prevalence of
HPV positive samples in our study is relatively low, but
higher than that found in cervical cancer cases from Mau-
ritius [15]. Similar low detection rates of HPV in archival
cervical tissue have been reported recently from Norway
[16].
In our study, all the HPV/DNA negative samples were
tested for β-globin gene. All were found to be β-globin
gene negative, although the β-globin gene primer used
was slightly longer than the very short primer used in the
DEIA reaction. Thus, the low detection rate is very likely
due to poor quality of the DNA in some archival tissue
samples. It has been demonstrated that suboptimal
processing of specimens in the histological process such
as the use of unbuffered formalin as a fixative, which was
common before 1970, may yield DNA that is unsuitable
for HPV detection [16]. In a subset of 200 samples from
the large international RIS HPV TT study, the HPV nega-
tive samples were further explored and 89% of them were
found to be β-globin gene negative, thus attributing this
relatively high rate of HPV negativity to the poor quality
of these retrospective samples. It was also found that ade-
nocarcinomas were more likely to be HPV negative than
squamous cell carcinomas [17].
HPV 16 and 18 are the major aetiological risk factors for
cervical carcinoma. Our overall prevalence of the two
major HPV types (16 and 18) was over 70%, which is sim-
ilar to the IARC multicentric case-control study by Castell-
sague et al. [1], the study by Hammouda et al. from
Algeria [18] that both used fresh samples and GP5+/6+
PCR assay, as well as the most recently meta analysis of
the published literature [9,10]. The study of Castellsague
et al. [1], which provides pooled data of eight case control
studies conducted in North Africa (Algeria, Morocco),
South America (Brazil, Paraguay, Peru) and South East
Asia (India, Thailand, Philippines), showed HPV 16 prev-
alence of cervical adenocarcinomas of 42.7%, HPV 18 at
31.8% and HPV45 3.8% [1]. However, regional differ-
ences were noticeable with a high prevalence of HPV 16 in
North Africa and South America, while in South East Asia
there was a high prevalence of HPV 18. A recent study
from Mozambique [19] on invasive cervical cancer
reported a similar prevalence of HPV 16 (about 47%) and
of HPV 16 and 18 combined (about 71%) as in our study.
Compared with the results of pooled analyses of invasive
cervical cancer from different continents [9,10,20], our
study presents a lower prevalence of HPV 16 (44.7%) than
in Europe, America, Northern Africa and South Asia but
comparable with Sub-Saharan Africa, while the HPV 18
prevalence is higher (28.8%) than in all regions [9]. Con-
sidering the adenocarcinomas only [1], the prevalence of
HPV 16 in our study is lower (35.0%) than in North Africa
(72.7%), South America (71.7%) and comparable with
Table 3: Multiple HPV genotypes in invasive cervical carcinoma 
cases with and without concurrent CIN lesions
HPV + (1 type) HPV + (>1 type) Total
No CIN 87 (96.7%) 3 (3.3%) 90
With CIN 1/2/3 18 (94.7%) 1 (5.3%) 19
Total 105 4 109
p > 0.05
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the prevalence in South-East Asia (34.6%). The prevalence
of HPV 18 in adenocarcinomas in our study (50%) is
somewhat lower than in South East Asia, but more than
twice higher than in the other regions.
The causes of the regional differences in HPV subtype
prevalence need clarification, e.g. the results from Mauri-
tius [15], where only HPV 18 was detected, warrants a fol-
low up study. The proportion of HPV types in the two
major histological types of cervical carcinoma, i.e. squa-
mous cell carcinoma and adenocarcinoma have been
noted to vary, although HPV 16 tend to predominate in
squamous carcinomas and HPV 18 in adenocarcinomas.
In the study of Bosch et al. [4] HPV 16 occurred in 51.2%
and 28% of squamous carcinomas and adenocarcinomas
respectively, while the prevalence of HPV 18 was 56% in
adenocarcinomas and 12.1% in squamous carcinomas. In
distinction from Bosch et al. results [4], our data shows a
lower prevalence of HPV 16 in squamous cell carcinomas
but a higher in adenocarcinomas, and a higher prevalence
of HPV 18 in squamous tumours, lower in adenocarcino-
mas. We also did not observe types 31, 39 and 52 in ade-
nocarcinomas, suggesting that these types may be less
commonly associated with risk of adenocarcinomas
which is in accordance with previously reported data [1].
The absence of these types was also found by other inves-
tigators [18,21] but not by the preliminary data of the RIS
HPV TT study [22].
One of the interesting findings of our study was the five
cases in which the samples were positive for HPV, but spe-
cific HPV genotypes could not be identified. This raises
the possibility that there may be some unidentified HPV
types or that some additional HPV types could have a
wider range of probes. In a study in Mozambique [23],
HPV specific types could not be identified in 19% of the
HPV positive cases, and this failure was attributed to the
limited number of HPV specific probes used.
Multiple infections were seen in only four HPV positive
cases (3.5%) in this study. This is similar to some previous
studies where the prevalence varied from 2.5% in Spain
and Columbia [5], 3.9% in Thailand [6], 4.3% in Brazil
[24], 7.9% in Morocco [25], and 12.9% in women with
squamous tumour in Peru [26]. However, much higher
rates were also reported by other workers, from 19.3% in
Paraguay [27], 32.2% in Korea [28], 32% in Costa Rica
[29] and 34.3% in Mozambique [30]. These differences
could be due to underlying prevalence of multiple infec-
tions in the various populations or to differences in the
methods used in detection and diagnosis [31].
Whether multiple HPV infections are involved in cervical
cancer pathogenesis is rather unclear. Herrero et al. found
that the risk of cervical cancer associated with HPV 16
alone is similar or greater than the risk associated with
multiple infections (HPV 16 plus other HPV) [29]. The
results of Lee et al. found multiple infections associated
with increased cervical cancer risk [32]. Although the
number of cases in our study is rather small, the results
have some important implications. If the HPV vaccines
under trial containing 16 and 18 antigens are close to
100% efficacy [11,13], then one could assume that about
70% of cervical cases would be prevented by the use of the
vaccine. It also raises the question whether other HPV
types should be included in future HPV vaccines. This is of
concern because of multiple infections or infection with
other common HPV genotypes which could account for
5% to 10% of cervical cancer cases. The results of our
study are in agreement with previous reports by Ham-
mouda et al. [18], and Castellsague et al. [1].
Our study had a number of strengths. The method we
used is sensitive and has high efficacy in comparison with
other methods using other general HPV primer sets [14].
In addition, extreme precautions were undertaken to
avoid contamination, and stringent SOP (standard of pro-
cedures) were applied throughout the study. To avoid
false positive results, controls consisting of non-tumour
tissue blank paraffin sections and other negative control
samples were simultaneously tested in each of the differ-
ent steps of analysis.
One limitation of our study was the relatively small
number of cases tested. Since the specimens came from
different parts of the country, the duration of fixation
were not uniform and could have contributed to some
cases being negative for HPV. In addition, the use of non
buffered formalin could also have deteriorated the DNA,
resulting in false negative results.
In our study we did not have information on HIV serol-
ogy. HIV infection is a risk factor for pre cervical cancer
lesions [33,34] and also probably for invasive cervical
cancer [34], although some earlier studies did not find any
associations [35]. Patients with HIV seem to have infec-
tions with a broader spectrum of HPV types other than
HPV 16, and more prone to simultaneous multiple HPV
infections. The prevalence of HIV in Uganda could have
been as high as 20% during part of the time when the
samples were collected. This is based on HIV sero-
prevalance among pregnant women which rose from 10%
in 1985 to around 30% in 1990–1992 [36]. Although this
is a very high rate of HIV, we did not detect in our samples
a different HPV genotype distribution of the most fre-
quent types, neither a higher number of multiple infec-
tions.
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Conclusion
The results of our study show that the HPV type distribu-
tion can be determined using existing archived biological
materials, such as paraffin blocks, allowing evaluating
changes over time, and reaffirm the role of HPV in cervical
cancer pathogenesis in the Ugandan population. HPV 16
and 18 account for about 75% of cases while about 20%
are due to other HPV genotypes, and the remaining due to
multiple HPV types. The results suggest that more HPV
types are yet be identified and recommend that future
HPV vaccines be tailored according to local HPV type dis-
tribution.
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The usefulness of immunohistochemistry in tissue
microarrays of Human Papillomavirus negative
adenocarcinoma of the uterine cervix
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Abstract
Background: The origin of adenocarcinomas presenting on the cervix uteri may be doubtful, i.e. whether it is of
cervical or endometrial origin, due to the overlapping morphological features. In HPV negative samples, further
tests may be needed to ascertain the nature of the tumours. We aimed to explore the use of
immunohistochemistry profiles in tissue microarrays in archived samples of adenocarcinoma (ADC) of the cervix
from Uganda that tested negative for HPV DNA.
Findings: Five commercially available antibodies were tested in tissue array sections immunostained utilizing the
avidin-biotin (AB) technique. In 26 ADC samples, HPV was detected in 13, p16 in 15 (8 in HPV positive and 7 in
HPV negative), CEA in 12, vimentin in 6, ER in 0, and PR in 2. Among the 13/25 HPV negative ADC samples, five
were positive for CEA suggesting endocervical origin, and three were vimentin positive (one had a mucinous
endocervical histological pattern and two were ADC, not otherwise specified, most likely of endometrial origin).
Conclusions: The immunoprofiles of ADC with the antibodies studied are rather nonspecific. By using
immunohistochemistry in 13 HPV negative ADC, endocervical tumour origin was suspected in five CEA positive
cases while two out of three vimentin positive samples were probably of endometrial origin, suggesting that CEA
and vimentin may be valuable in distinguishing HPV negative cervical adenocarcinomas from endometrial
adenocarcinomas.
Background
Although the role of HPV in cervical adenocarcinoma
appears well established [1-3], the nature of adenocarci-
noma arising from the cervix may be difficult to define
due to the overlapping morphological features between
cervical adenocarcinomas and endometrial adenocarci-
nomas. While endocervical adenocarcinomas express
p16 and CEA [4] and whereas endometrial adenocarci-
nomas usually showed vimentin and hormonal receptors
[5], the results may be inconclusive. However, CEA has
been reported to be expressed in both cervical and
endometrial adenocarcinomas [6], while the expression
of vimentin was noted to be weak and focal in many
endometrial adenocarcinomas [5]. An alternative view is
that some expression of these markers may reflect dif-
ferentiation (mucinous versus endometrioid) compared
to the histogenetic site of origin (endometrial versus
cervical) [7]. In order to resolve the problem, HPV test-
ing has been used in attempts to distinguish these
tumours [8]. Extending this approach, a recent study
evaluated the use of HPV DNA, p16 and hormonal sta-
tus to determine the origin of cervical tumours [9].
HPV negative adenocarcinomas in the same site may
originate either from cervical or endometrial cells. We
postulated that immunohistochemistry could be of use
in HPV negative cervical tumours from Uganda.
We aimed to explore the utility of immunohistochem-
istry profiles, i.e. the expression of p16, carcinoembryo-
nic antigen (CEA), vimentin, estrogen receptor alpha
(ER) and progesterone receptor (PR), in tissue microar-
rays in archived samples of ADC that had been tested
for HPV DNA, and in particular to assess if it would be
possible to define the tissue of origin of HPV negative
adenocarcinoma samples. This was based on the use of
CEA as a marker of endocervical ADC, vimentin and
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hormone receptors (markers more related to endometrial
ADC) and p16 as a proxy marker for HPV infection. p16
is a protein encoded by p16INK4a gene and has been
used as an indirect assay for HPV infection [10]. CEA is
an onco-fetal protein which has been touted as a useful
antibody in distinguishing between endocervical
adenocarcinoma and endometrial adenocarcinoma [6].
Vimentin is characteristically positive in endometrial ade-
nocarcinoma [5], although positivity has also been
reported in cervical adenocarcinomas [6]. ER and PR are
usually positive in endometrial adenocarcinoma and
negative in endocervical adenocarcinoma [4]. They are
used usually to exclude endocervical origin of tumours.
Materials and methods
Cervical carcinoma samples were retrieved from the
archives of the Department of Pathology, Makerere Uni-
versity, Kampala, Uganda, and were diagnosed during
the period 1968-1990. The study protocol has been
approved of Higher Degrees Research & Ethics Commit-
tee at Makerere University, Uganda.
HPV testing
The cervical carcinoma samples sections selected for
HPV testing were digested with proteinase K and the
resulting extract was used for PCR. SPF10 PCR was per-
formed using 10 μl of a 1:10 dilution of the DNA extract
in a final reaction volume of 50 μl. The amplified PCR
products were tested using probe hybridization with a
cocktail of conservative probes recognizing at least 54
mucosal HPV genotypes in a microtiter plate format for
the detection of HPV DNA. Optical densities (OD450)
were read on a microtiter plate reader. HPV DNA posi-
tive samples were subsequently analysed by HPV SPF10-
LIPA25 (version 1: produced at Labo Biomedical Pro-
ducts, Rijswijk, The Netherlands) [10,11], a reverse
hybridization technique that detects 25 high-risk and
low-risk HPV types (6, 11, 16, 18, 31, 33, 34, 35, 39, 40,
42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 66, 68, 70, 74).
The sequence variation within the SPF10 primers allows
the recognition of these different HPV genotypes, except
for the types 68 and 73 as their interprimer regions are
identical and cannot be distinguished on this test. After
PCR, 10 μl of the amplimers was used to perform
reverse hybridization for HPV genotype identification.
The positive hybridization on the strips is visualized as a
purple band by means of a precipitating colour substrate
on the probe site. All SPF10-LIPA25 PCR detection and
typing was performed at the facilities of DDL Diagnostic
Laboratories (DDL, Voorburg, Netherlands) and at Insti-
tut Català d’Oncologia (ICO, Barcelona). Detailed HPV
results were published elsewhere [12].
Tissue Microarrays (TMA)
Three punches (gauge 1 mm) of pre-existing paraffin
embedded tissues were obtained from each block and
then re-embedded in an arrayed master block using the
manual tissue microarrayer (Beecher Instruments, Silver
Spring MD). The punch specimens were performed in
the most representative areas of the tumours, discarding
necrosis or artefacts. Four micron paraffin sections were
cut from the TMA blocks and deparaffinised through
alcohols and xylene before immunostaining.
Immunohistochemistry (IHC)
Monoclonal antibodies included: CEA (clone B0194-
11M-P, BioGenex), p16 INK4a, p16 (clone JC8, Biocare
Medical), Vimentin (clone V9, Dako), estrogen receptor
alpha, ER (clone 1D5, Dako), progesterone receptor, PR
(clone PgR 636, Dako).
Heat Induced Epitope Retrieval (HIER) was done
using a pressure cooker as a heating device. Retrieval
solutions that were used were: Citrate buffer for Vimen-
tin, PR, ER; EDTA 10% for p16 and Saponin for CEA.
Incubation was done at room temperature for 30 min
for all the antibodies.
The Dako Autostainer universal staining system was
used with the EnVision+ Dual Link System-HRP, a two-
step IHC staining technique. This system is based on an
HRP labelled polymer which is conjugated with second-
ary antibodies.
The final reaction was done with diaminobenzydine
and slides were counterstained with hematoxylin. The
immunohistochemical stains were interpreted by one of
the authors (BL) and the results were reported as posi-
tive or negative using the following criteria for each
antibody. ER and PR were considered positive when
more than 10% of the tumour cells displayed nuclear
positive staining. p16 was considered positive/overex-
pressed if more than 75% of the tumour cells showed
cytoplasmic and/or nuclear staining, CEA was consid-
ered as positive if more than 10% of the neoplastic cells
showed cytoplasmic positive staining, and vimentin was
considered positive only when more than 20% tumour
cells displayed cytoplasmic staining. The cut-offs for
most antibodies were those used at laboratory in Barce-
lona, while the 75% for p16 was chosen because this
cut-off is both sensitive and specific for HPV related
cervical adenocarcinoma [13].
Statistical analysis
The chi-square test was used to determine significant
differences between HPV positive and HPV negative
adenocarcinomas and expression of, p16, CEA, ER, PR
and vimentin.
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Results
In total 26 samples were successfully analysed for HPV
and immunohistochemistry. In these, HPV DNA was
detected in 13/26 (50%) of ADC (Table 1). Overexpres-
sion of p16 was detected in 15/26 (57.7%) ADC. Of the
15 p16 positive cases, 8 (53.3%) were HPV positive and
7 (46.7%) were HPV negative. The reactivity was both
cytoplasmic and nuclear in positive samples.
CEA was positive in 12/25 (48%) ADC (Table 1). Of
these, seven were HPV positive and five HPV negative.
All five HPV negative and CEA positive had histological
features of endocervical ADC, suggesting endocervical
origin (Table 2). Vimentin was positive in 6/26 (23.1%)
ADC, three of them being HPV positive. Of the three
HPV negative cases, one had a mucinous endocervical
histological pattern and two were ADC not otherwise
specified (NOS), most likely of endometrial origin. ER
was not detected in any sample and PR were positive in
two samples, both HPV positive (Tables 2 and 3). Seven
ADC samples were negative for all the three markers, of
these two were HPV positive. Among the other five
samples, two had endocervical histological features,
two were serous, and one was ADC NOS. (Table 2).
The positivity for each of the immunohistochemistry
markers did not differ in HPV positive and negative
ADC (Table 3, Figure 1).
Discussion
Histological subtypes of endocervical and endometrial
ADC have some overlapping features, and poorly differ-
entiated tumours or small biopsies are difficult to
classify.
The differential diagnosis between endocervical and
endometrial ADC is a common problem in surgical
pathology, that can be approached using different
immunohistochemical antibodies, the most accepted
panel markers being CEA (as a marker of endocervical
ADC), vimentin and hormone receptors (markers more
related to endometrial ADC). HPV DNA detection by
molecular techniques has proved valuable [8]. However
in our series we found a much higher percentage of
HPV negative ADC (50%) than we expected.
As a comparison, 85% of samples were positive in the
whole series of the RIS TT study, which used similar
HPV testing methods [14]. This could probably be
explained by poor sample processing conditions in
Uganda, including problems in sample transport, type of
fixative (inconsistent use of buffered or non-buffered
formalin) and duration of fixation, leading to poor DNA
and protein preservation and consequently immunohis-
tochemistry and PCR with equivocal results.
Overexpression of p16 has been used as a surrogate
marker of high risk HPV infection [10]. Only 57.7% of
Table 1 HPV positivity and immunohistochemistry
markers in cervical adenocarcinomas (ADC)
Adenocarcinoma (ADC)
HPV positivity 48.1% (13/26)
p16 ≥ 75% 57.7% (15/26)
CEA > 10% 48.0% (12/25)
Vimentin ≥ 20% 23.1% (6/26)
ER ≥ 10% 0.0% (0/26)
PR ≥ 10% 7.7% (2/26)
Table 2 Immunohistochemistry patterns by HPV positivity in archival adenocarcinoma samples from Uganda*
HPV positive (N = 12/25) HPV negative (N = 13/25)
CEA Vimentin ER PR % with this pattern % with this pattern Histological subtype
+ - - - 58.3% (7/12) 38.5% (5/13) Mucinous Intestinal (2)
Mucinous Endocervical (1)
Mucinous NOS (1)
NOS (1)
- + - + 16.7% (2/12) 0.0% (0/13) -
- + - - 8.3% (1/12) 23.1% (3/13) Mucinous Endocervical (1)
NOS (2; probable endometrial)†
- - - - 16.7% (2/12) 38.5% (5/13) Mucinous Endocervical (1)
Mucinous Villoglandular (1)
NOS (1)†,§
Serous (2; probable endometrial)†
*Out of the 26 samples 25 were stained with all the antibodies and HPV tested.
†After immunohistochemistry and histological subtype diagnosis an endometrial origin cannot be discarded.
§No further classification because of lack of markers.
Table 3 Immunohistochemical stains by histological
subtype of cervical adenocarcinoma*
HPV + HPV- p value
p16 (+) 8/12 7/13 0.69
CEA (+) 7/12 5/13 0.53
Vimentin (+) 3/12 3/13 1.0
PR (+) 2/12 0/13 0.22
ER (+) 0/12 0/13 -
*Out of the 26 cases, histological sections stained with all the antibodies were
available in 25.
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our ADC samples were p16 positive; considering the
probable rate of false negative of 15% (the rate of false
negative in SCC) we should have about at least 25% (i.e.
57.7% + 15% = about 75%; 100% - 75% = 25%) of p16
negative ADC samples that remain unexplained. Being a
usual problem in diagnosis, the possibility of endome-
trial cancer has to be considered. Moreover, p16 itself
cannot be considered an ideal marker of HPV infection
in ADC, since many samples of HPV negative cervical
ADC have also been found to express p16 [15]. This
raises the possibility of HPV-independent mechanisms
of p16 overexpression in some cervical ADC, similar to
what has been observed in Bowen’s disease [16]. Besides,
some endometrial cancer can also display overexpres-
sion of this marker [5]. Among the 13 HPV negative
ADC, there were some features that support endocervi-
cal origin, i.e. CEA expression in five cases and the his-
tological features were in favour of endocervix in three
others although IHC results were inconclusive. Other
studies have also found that CEA is usually positive in
cervical ADC, although some samples may be negative
[4,17,18]. Three of our samples showed vimentin expres-
sion which is usually related to endometrial origin [5],
however one of them displayed a morphological pattern
suggestive of endocervical differentiation. The expres-
sion of vimentin in cervical ADC has been reported pre-
viously [6]. The absence of ER and low expression of PR
is not surprising, considering that few samples of cervi-
cal ADC are usually ER or PR positive [4].
Thus, endocervical origin seems confirmed in some
samples, endometrial cancer were suspected in four
others (two vimentin positive and two without conclu-
sive IHC results but were serous ADC) and one could
not be further classified due to lack of histological or
IHC markers.
In view of overlapping and diverge morphologic
heterogeneity of both cervical and endometrial
adenocarcinomas, the results of this study suggest that the
use of a number of markers appear useful in distinguish-
ing the two tumours in HPV negative cases. In a clinical
setting, one could use a combination of p16, CEA and
vimentin in cervical tumours to determine possible site of
origin. Another relevance of our results is in correct clas-
sification of cervical tumours for epidemiological research.
Our study has a number of strengths: only areas with-
out necrosis were sampled, the use of tissue microarray
techniques allowed uniform conditions during immuno-
histochemical staining, making the results more compar-
able, and all specimens were tested for HPV using
sensitive methods.
Our study also has some limitations, such as the small
number of samples studied, the probable variation in
the fixation of the tissues due to the fact that samples
came from different areas of Uganda, leading to loss of
antigen epitopes. In particular, estrogen and progester-
one receptors are known to be quite labile antigens.
Conclusion
In summary, our results showed overlap in expression of
p16, CEA and vimentin between HPV positive and HPV
negative cervical ADC, and suggest that some samples
among the HPV negative ADC, diagnosed as cervical
ADC, may be of endometrial origin. In our series
amongst 13 HPV negative samples, the endocervical ori-
gin seems probable in five CEA positive samples while
two vimentin positive samples are suspected to be endo-
metrial cancer. Although the number of samples studied
are too few to draw definite conclusions, it suggests that
CEA and vimentin may be of value in distinguishing
HPV negative cervical tissue from endometrial ADC.
List of abbreviations
ADC: adenocarcinoma; CEA: carcinoembryonic antigen;
ER: estrogen receptor; HIER: Heat Induced Epitope
Figure 1 Adenocarcinoma. Hematoxylin-eosin (a), p16 positive staining (b) and vimentin positive staining (c).
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Abstract  
 
Background: While the association of HPV with cervical carcinoma is well established, 
the influence of HIV on the risk of cervical carcinoma in sub Saharan Africa remains 
unclear.  To assess the risk of invasive cervical carcinoma associated with HIV and HPV 
types, a hospital-based case-control study was performed between September 2004 and 
December 2006 in Kampala, Uganda. Incident cases of histologically confirmed invasive 
cervical carcinoma (N = 316) and control women (N = 314), who were visitors or care-
takers of cervical carcinoma patients in the hospital, answered a standardized 
questionnaire including demographic, socioeconomic data, sexual behaviour patterns, 
medical and obstetrical history. Blood samples were obtained for HIV serology and CD4 
counts. Cervical samples were obtained using a cytobrush (control women) or cervical 
biopsy (invasive cervical cancer women). HPV DNA detection and genotyping was 
performed using the SPF-10/DEIA/LiPA25 technique, which detects all anogenital HPVs 
by DEIA and identifies 25 HPV genotypes by LiPA version1. Samples that could not be 
typed with any of the 25 genotypes were designated as HPV X. Odds ratios (OR) and 
95% confidence intervals (CI) were calculated by logistic regression, adjusting for 
possible confounding factors.  
Results: For both squamous cell cervical carcinoma (SCC) and adenocarcinomas, 
statistically significantly increased ORs were found among women infected with any 
HPV, in particular single HPV infections, infections with HPV16- related types and high-
risk HPV- related types, in particular HPV16, 18 and 45. For other HPV types the ORs 
for both squamous cervical carcinoma and adenocarcinomas were not statistically 
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significantly elevated. There was no overall association between HIV infection and risk 
of invasive cervical squamous cell carcinoma or adenocarcinoma after adjustment for 
CD4 decrease and HPV infections.  
Conclusions: The OR for squamous cervical carcinoma and adenocarcinomas were 
increased in women infected with HPV, in particular single HPV infections, infections 
with HPV16- and 18- related types, infections with high-risk HPV types,  
specifically with HPV types 16, 18 and 45. Cervical cancer was not statistically 
associated with HIV infection per se, and HIV positive women did not have a higher OR 
for cervical cancer in relation to HPV types.  
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Background 
 
Human papillomavirus infection (HPV) is a necessary cause for the development of 
cervical carcinoma, the risk differing [1] according to HPV type of infection. Infection 
with the human immunodeficiency virus (HIV) has also been associated with the risk for 
cervical carcinoma [2], the risk apparently varying according to co-infection with 
different HPV types [3,4]. The association between HIV and cervical cancer appears to 
be less evident in low income countries, notably in Sub-Saharan Africa, than in high 
income countries [5,6]. Two studies which were conducted at the beginning of the AIDS 
epidemic from Uganda [7] and Tanzania [8] which assessed HIV and cervical carcinoma, 
showed  no association. However, positive association has been observed in Western 
countries such as Italy, France, Spain [5,9,10] as well as in some recent studies from 
Uganda [11] and Tanzania [12]. Whether these differences in cervical cancer risks 
between studies can be explained by differences in co-infection with specific HPV types 
remains unclear. 
  
We present here results from a study of invasive cervical cancer in Uganda in relation to 
HPV and HIV infections, where the estimated world-standardized incidence rates of 
cervical cancer is rising and is now 52.4 per 100 000 women [13]. 
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Methods 
 
We conducted a hospital based case-control study in Mulago Hospital in Kampala, 
Uganda, which is the national referral and teaching hospital for Makerere University. The 
hospital admits about 10 cases with invasive cervical cancer each month. 
Patients attending the Gynaecological clinics or emergency section are mostly residents 
of Kampala City and the surrounding areas, with a population of about 1 000 000, 
although some come directly from areas outside Kampala. Like most urban areas of 
Uganda, HIV prevalence is relatively high in Kampala [14]. Recruitment of cases and 
controls was done by selected nurses and midwives working in the gynaecological wards 
or clinics using the inclusion and exclusion criteria described below.  
 
Recruitment of invasive cervical cancer cases 
Patients eligible for the study were women aged 18 to 74 years, residents of Uganda for at 
least two years, consecutively diagnosed with incident invasive cervical carcinoma during 
the period September 2004 and September 2006. They had not yet undergone primary 
treatment for cervical cancer, and they gave an informed consent to participate in the 
study and were able to provide biological samples. Patients were excluded if tissue and 
blood samples could not be collected because they were in a terminal stage or for any 
other reason that might interfere with established patterns of patient care.      
 
Recruitment of control women  
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At the Mulago Hospital, all hospitalised patients have with them one or more 
accompanying persons who are responsible for preparing food and taking care of the 
basic needs of hygiene and other requirements of the patients. These accompanying 
persons are in general female members of the same family or clan. Control women were 
recruited among those accompanying or visiting cervical cancer patients. The motivation 
to enrol relatives of the cancer patients as controls was to avoid bias by inclusion of 
control women who would most probably live in the same areas of the country as the 
cancer cases and would have a similar social background. They would probably also have 
used the same hospital as the cases if they had had a cervical cancer diagnosis. Since the 
evaluation of family history of cervical cancer was not among our study hypothesis, the 
inclusion of blood relatives of the cervical cancer patients did not constitute a problem.  
Control women were frequency matched to cervical cancer cases by 5-year age intervals. 
Inclusion criteria were the same as for cases (i.e. resident of Uganda for at least two 
years, aged 18 to 74 years between September 2004 and December 2006, ability to give 
informed consent and willing to provide biological samples), except for the cervical 
cancer diagnosis.  
Control women were offered a pelvic examination with visual inspection of the cervix 
uteri and Pap smear screening test. The results were made available before they left the 
hospital (i.e. during the case patient period of hospitalization). Women in whom pre-
malignant and malignant cervical abnormalities were suspected or detected were referred 
for a standard follow-up diagnosis and treatment at the Mulago Hospital. A symptomatic 
diagnosis of cervical and vaginal infections was done by the gynecologists examining 
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control women, and appropriate antibiotic treatment was offered free of charge whenever 
indicated.    
 
Collection of biological samples and study procedures 
Information about reproductive history, lifestyle and sexual practices was assessed using 
a standardized questionnaire administrated by the nurses or midwives recruiting cervical 
cancer cases and control women.  
All subjects underwent pelvic and abdominal examinations. Cervical samples were 
obtained for diagnosis and HPV detection. Blood was obtained for full blood count, HIV 
serological testing, and CD4 counts.  
 
HIV testing and CD4 counts 
HIV was measured using a rapid test [15] which was the recommended test in Uganda 
during the study period (Ministry of Health of Uganda). Briefly, blood was initially tested 
by the Capillus method (Capillus HIV-1/HIV-2 (CP) (Trinity Biotech, Galway, Ireland). 
Negative results were reported as negative, and no other confirmatory test was done. For 
positive results, a confirmatory test using Serocard (Trinity Biotech, Galway, Ireland) 
was performed. When results from Serocard were positive, it was reported as positive. 
However, if the results from Serocard were negative, a tiebreaker test using the Multispot 
test (Bio-Rad Laboratories) was applied, and the result reported as negative or positive, 
depending on the result of this test. All tests were done according to the manufacturer’s 
instructions. HIV was assessed as positive (exposed) or negative (not exposed). These 
tests algorithms have 100% sensitivity and specificity [15]. The CD4 counts were done 
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using flow cytometry with the Becton Dickinson FACSCount automated instrument (BD 
FACSCount™).    
 
Cervical cell samples 
For women with invasive cervical carcinoma, biopsies of the cervical lesions were 
collected under general anesthesia. Samples were immediately stored into sterile 
specimen tubes and transported in a flask containing ice to the pathology laboratory. 
There the specimen was divided into two parts: one part was fixed in 10% buffered 
formalin (for 12 to 24 hours) for histological processing and diagnosis, and the other half 
was kept in a Nuc tube, labelled and stored at -70oC until shipped for HPV analysis. 
Biopsy samples were processed using the automatic tissue processor; they were paraffin 
embedded, sectioned at 4 µm thickness and stained with Haematoxylin and Eosin.  
 Exfoliated cervical cells were collected before any treatment from control women with 
two Cervex brushes. The first brush was rinsed in PreservCyt solution (ThinPrep, Cytyc 
Corporation) according to the manufacturer’s instructions and kept at room temperature 
until shipped to the laboratory for HPV testing. The second brush was used to make a 
smear and stained with Pap stain; smears were classified as normal or abnormal.   
All histological and cytological diagnoses were done by a pathologist at the Department 
of Pathology, Makerere University. 
 
HPV testing 
The frozen invasive cervical carcinoma samples and the exfoliated cervical samples 
(inThinPrep) from control women were shipped to Delft Diagonstic Laboratory (DDL) in 
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Voorburg, the Netherlands, for HPV analysis. Frozen samples were shipped in dry ice, 
while Thin Prep samples were shipped at room temperature. DNA was extracted from the 
frozen sections of cervical tissue samples using proteinase K. From the suspension of 
cervical cells, DNA was isolated by use of a MagNA Pure LC instrument (Roche 
Diagnostics) using the total nucleic acid isolation kit (Roche Diagnostics).  
SPF10 PCR was performed using 10 µl isolated DNA in a final reaction volume of 50µl. 
Ten µl of the amplified PCR products were tested with a cocktail of general probes 
recognizing at least 54 mucosal HPV genotypes in a microtiter plate format for the 
detection of HPV DNA by use of DNA enzyme immunoassay (DEIA). Optical densities 
(OD450) were read on a microtiter plate reader. Subsequently, for HPV DNA positive 
samples 10µl of the same SPF10 amplimer was genotyped by the SPF10-LiPA25 test 
(version 1, produced at Labo Biomedical Products, Rijswijk, The Netherlands). By 
reverse hybridization of the SPF10 amplimer with 28 different probes on the LiPA strip 25 
HPV genotypes can be identified:  HPV6, 11, 16, 18, 31, 33, 34, 35, 39, 40, 42, 43, 44, 
45, 51, 52, 53, 54, 56, 58, 59, 66, 68/73, 70, 74). The sequence variation within the SPF10 
primers allows the recognition of these different HPV genotypes, except for the types 68 
and 73, as their innerprimer regions are identical and cannot be distinguished in this test. 
The positive hybridization on the strips is visualized as a purple band by means of a 
precipitating colour substrate on the probe site. Samples that were HPV DNA positive 
with SPF10 PCR-DEIA, but for which no type was identified by the LiPA25 strip were 
designated as HPV type X. 
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For invasive cervical cancer cases that were HPV negative, a beta-globin PCR was 
performed to assess the quality of DNA isolated from the biopsy tissue samples tested 
negative for HPV DNA. 
 
Ethical consideration 
The study protocol was approved by the Higher Degree’s Research Committee of the 
Faculty of Medicine, Makerere University and the Uganda National Council of Science 
and Technology. The study also complied with the ethical norms of Mulago Hospital and 
those of the Ministry of Health of Uganda. All the study participants gave a written 
informed consent before inclusion into the study. 
 
Data analysis 
To evaluate the risk of cancer, SCC and adenocarcinoma separately, odds ratios (OR) and 
the associated two-sided 95% confidence intervals (CI) were calculated using logistic 
regression models. To address the problems of small sample sizes, we calculated the 
logistic regression using Firth’s penalized likelihood approach [16]. As a consequence of 
the small sample sizes, only the lower or upper bound of the confidence interval was 
possible to estimate for some ORs. We fitted age-adjusted models for each HPV type or 
groups of HPV types, as well as models also adjusting for HIV (positive or negative) and 
CD4 count per 100 cells, as a linear continuous variable(s).  
 The combined groups of HPV types analyzed were “any HPV infections”; “single HPV 
infections” for any HPV infection except HPVX, “multiple HPV infections”, i.e. 
concomitant infection with more than one HPV type , except for HPVX, ”high-risk HPV” 
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for infections with any of the HPV types 16, 18,  31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68 
or 73; ”low-risk HPV” for infections with any of the HPV types 6, 11, 34, 40, 42, 43, 44, 
53, 54, 66, 70 or 74; ”HPV16- related” for any of the HPV types 16, 31, 33, 35, 52 or 58; 
”HPV18- related” for any of the types 18, 39, 45, 59 or 68; and HPVX. 
 
The statistical software SAS version 9.2 procedure logistic was used for all analyses. All 
tests of statistical hypotheses were made on the two-sided 5% level of significance. 
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Results 
 
During the study period, 484 women with a preliminary incident cervical carcinoma 
diagnosis and 385 control women were approached and invited to participate in the study. 
Sixty six (66) potential cervical carcinoma cases and 22 control women declined to 
participate, and 41 cases and 44 control women were excluded due to incomplete 
questionnaires or inability to provide any samples for different reasons. Further, 61 
potential cases were excluded because the diagnosis of invasive cervical cancer was not 
confirmed by histology, as well as 5 control women who had cervical lesions compatible 
with cervical intraepithelial neoplasia (CIN). Thus, a total of 316 invasive cervical cancer 
cases (265 squamous cell carcinomas, 42 adenocarcinomas, 5 of mixed histology and 4 
other histology) and 314 control women were preliminary recruited into the study. From 
these, cervical samples for HPV testing were obtained in 255 invasive cervival cancer 
cases (215 were squamous cell carcinomas, 32 adenocarcinomas and eight (8) were other 
histological types) and 309 controls. Of 255 invasive cervical cancer cases tested for 
HPV, 16 had to be excluded because their samples were beta-globin negative, leaving 
239 cases in the final analysis. The details of the enrolment are shown in Table 1.  
 
The clinical and demographic characteristics of study participants are shown in Table 2. 
A smaller proportion of cases than controls had ever had a Pap smear taken, and cases 
had proportionally more HPV infections than controls. 
Of the 239 cases and 309 controls, HPV genotypes were detected in 222 (92.9% of 239) 
of cases and 95 (30.7% of 309) of control women. Seventeen cases (7.1%) were HPV 
negative. 
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There were no other statistically significantly differences between cases and controls 
regarding characteristics, including HIV positivity. The HIV test was positive in 55 
(18.8%) cervical cancer cases and 54 (17.5%) control women. 
 
Squamous cell carcinoma (SCC) and HPV 
For SCC, the age-adjusted ORs were statistically significantly increased for any HPV 
positive (OR 50.8, 95% CI: 25.8-113.9), single HPV infections (OR 33.3, 95% CI: 20.2-
56.7), HPV16- related types (OR 11.6, 95% CI: 7.5-18.5), HPV18- related types (OR 9.4, 
95% CI: 5.3-17.4), and high-risk HPV types (OR 64.5, 95% CI: 35.4-126.6), in particular 
HPV16 (OR 29.1, 95% CI: 15.4-60.7), HPV18 (OR 9.6, 95% CI: 4.6-22.3), and HPV45 
(OR 58.7, 95% CI: lower limit >7.9). 
Multiple HPV infections and infections with low-risk HPV types were not associated 
with increased an OR for SCC. Adjustment for HIV as well as CD4 count decline did not 
change substantially the OR estimates with the different HPV types (Table 3).  
 
Squamous cell carcinoma according to HPV and HIV 
The association between different types of HPV infections and SCC was rather similar in 
women who were HIV negative and HIV positive, although the number of HIV positive 
SCC cases in our study (N = 42) was limited, and therefore the confidence intervals of 
our OR estimates were rather broad (Table 4).   
 
Adenocarcinoma and HPV 
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The OR for adenocarcinoma were statistically significantly increased for any HPV 
positive (OR 12.9, 95% CI: 5.0-41.8), single HPV infections (OR 13.7, 95% CI: 6.0-
34.0), HPV16- related infections (OR 3.6, 95% CI: 1.5-8.2), HPV18- related infections 
(OR 22.8, 95% CI: 9.3-58.9), high-risk HPV infections, in particular with HPV 16 (OR 
11.6, 95% CI: 4.3-31.8), 18 (OR 18.5, 95% CI: 6.6-54.4) and 45 (OR 297.4, 95% CI: 
lower limit >26.4). Adjustment for HIV as well as CD4 count decline did not change 
substantially the OR for the different HPV types (Table 5).  
 
Adenocarcinoma according to HPV and HIV infection 
Given the very low number of HIV positive adenocarcinoma cases (N = 4) in our study, 
our risk estimates are not sufficiently precise to reach any conclusions about differences 
between HIV negative and positive women, but there was no suggestion of a risk 
difference (Table 6). 
 
Table 7 shows the overall OR for SCC and adenocarcinoma in relation to HIV infection. 
In statistical models adjusting for age and CD4 count, HIV positive women had an 
increased OR for SCC (OR 1.6, 95% CI: 1.0-2.6). However, after further adjusting for 
different HPV infections, the OR became no longer statistically significant (adjustment 
for age, CD4 and any HPV infection: OR 0.8, 95% CI: 0.4-1.4), except when we only 
adjusted for low-risk HPV infections (OR 1.9, 95% CI: 1.1-3.2) and multiple infections 
(OR 1.8, 95% CI: 1.1-3.0), when the lower confidence intervals were of borderline 
statistical significance. There was no evidence of association between HIV infection and 
adenocarcinoma in any of the statistical models tested.  
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Discussion 
 
The HPV types associated with both SCC and adenocarcinoma risk in our study has also 
been found to be associated with the most invasive cervical carcinoma in other regions of 
the World [17,18]. 
 
Squamous cell carcinoma 
Our study shows that SCC in Uganda is strongly associated with any HPV infections and 
high-risk HPV infections, in particular high-risk infections with HPV16 (and related 
types), 18 (and related types) and 45. We found no evidence that adjustment for HIV 
infection or CD4 decline affect the OR significantly, or that HIV infection per se was 
associated with SCC.  
As in our study, several earlier studies found HPV16 predominating in squamous cell 
carcinomas  [19]. Our study showed higher ORs for SCC associated with HPV16 (OR 
29.1, 95% CI: 15.4-60.7), which is similar to a study from Taiwan by Chen et al. [20], 
where the HPV16 was associated with an OR of 67. The Taiwanese study found 
substantial elevated risks for SCC associated with HPV52 (OR = 3.04) and HPV58 (OR 
= 5.22), which were not confirmed in our study, while the risks for SCC with the other 
HPVs were low. A study from Mexico also found a high risk of cervical carcinoma for 
HPV16 and 18 [1]. The results from Mexico are exceptional in that the OR for HPV18 
was higher than that of HPV16. High risks for HPV18 have also been previously reported  
by a number of authors [21-23]. Low risks for HPV18 have been found in some studies 
from India [24,25].  
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Adenocarcinomas 
For adenocarcinomas, we found an association between infections with any HPV 
infections, in particular single infections, infections with high-risk HPV types, most 
importantly HPV16 (and related types), 18 (and related types) and 45. Adjustment for 
HIV infection and CD4 decline did not alter the associations meaningfully, suggesting the 
little confounding effect of HIV and its associated immune dysfunction on the risk of 
HPV in cervical carcinoma. The number of HIV positive cases in our study was rather 
small, and therefore no firm conclusion could be reached regarding any differences in the 
association between HPV infections in HIV positive and negative women.  
HPV18 has been reported as the most frequent HPV type found in adenocarcinomas [19]. 
In a pooled analysis of case-control studies, the relative risk of HPV18 in cervical 
adenocarcinoma was high (OR 410.32, 95% CI: 167.44 to ∞ ) [4]. These results were 
much higher then ours for HPV18 (OR 18.5, 95% CI: 6.6-54.4). 
These differences in findings in different studies may indicate that regional factors, such 
as differences in the prevalence of different types of HPV infections, may affect cervical 
carcinoma risks [26]. These differential risks are probably due to pathogenesis of the two 
major types of cervical carcinoma [27]. Smith et al. [28] and Madeleine et al. [29] noted  
an elevated risk of SCC associated with trichomonas, but no associated increased risk for 
adenocarcinoma. Another factor which could in theory explain the differences in risks of 
squamous cell carcinoma and adenocarcinoma is smoking [30]; however smoking is not 
common in Uganda with a prevalence of 3% among adult women [31] and 5.3% among 
adolescent girls [32]. The relatively low relative risk of cervical carcinoma due to other 
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high-risk HPV types (besides HPV16, 18 and 45) is supported by the low prevalence of 
these HPV types in cervical carcinomas in several other studies [3,33], including a recent 
study by de Cremoux et al. [34] who found that up to one third of cervical carcinomas 
were not associated with HPV16 or 18. Some of these high-risk types, namely HPV31, 
33, 52 and 58 have been found to be more prevalent in high grade intraepithelial cervical 
lesions than in invasive squamous cell carcinomas [17]. 
 
HIV 
Of particular interest was the lack of effect of HIV infection and associated reduction of 
CD4 count on the risk for cervical carcinomas. After controlling for HPV infections in 
the statistical models, the association between HIV and SCC became non-statistically 
significant for most HPV infections, except low-risk and multiple infections, while there 
was no association between HIV and adenocarcinomas, regardless of which statistical 
adjustment we did in the models. 
The lack of excess increased risk of cervical carcinoma as a result of HIV infection could 
be explained by the fact that progression of intraepithelial neoplasia to invasive 
carcinoma are multifactorial, and not dependent on immune status only [35], and the 
existence of slow progressors [36,37] or elite controllers [38,39] in some women. Lastly, 
infections with HIV may have occurred too late in life to have any effect on HPV 
infections, as suggested by a study from Nairobi, Kenya [40].  
 
Several previous studies have shown varying risk of cervical carcinoma in association 
with HIV infection [12,41-44]. Earlier studies suggested that a possible increase of 
19 
 
cervical cancer risk among HIV positive women could be attributed to the increased 
prevalence of HPV infection, persistence of HPV infection and pre-invasive cervical 
carcinoma [45]. In addition, CIN is less likely to regress in HIV-infected women [46]. 
This has been attributed to reduced HLA class II molecules and the presence of immature 
Langerhans cells within the cervical tissue in HIV-infected women [47]. However, our 
study did not corroborate the hypothesis that HIV infection would increase a woman’s 
risk for invasive cervical cancer, and the OR associated with different HPV infections 
and cervical cancer risk were similar in HIV positive and negative women, except for 
low-risk and multiple infections for SCC. This could be attributed to the role of impaired 
immunity as previously suggested [45,46]. Other studies have suggested that HPV types 
other than 16 or 18 are more prevalent in HIV positive women [19,48], and that the 
median duration of infections with different individual HPV types lasts longer in HIV 
positive women as compared to HIV negative women, with the exception of HPV16 
which is similar [49,50].  
 
Our study had a number of advantages compared to previous studies. We enrolled all 
consecutive patients with lesions suspected to be invasive cervical cancer, aiming to 
reduce bias that could occur if any criteria associated with the exposure were used to 
select cases, for example stage, duration of symptoms, tribe, etc. While other studies have 
used women with other disease conditions as controls [11,12], we were able to use 
women who were not hospitalised, had no cervical disease (CIN cases were excluded), 
and were living in the same geographical areas as cancer cases. Further, they were 
representative of the population base from where the cases arose. Since the evaluation of 
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family history of cervical cancer was not among our study hypothesis, the inclusion of 
blood relatives of the cervical cancer patients as controls did not constitute a problem.  
 
Another strength was that we carried out the study in an area where both HIV prevalence 
[14] and cervical carcinoma incidence are high [13]. This allowed us to adjust for HIV 
status and decline in CD4 counts in our HPV analysis, as well as to perform stratified 
analysis by HIV status to assess the impact of HIV infection per se and the HPV risk 
associated with HIV status on cervical carcinoma.  
 
Some possible confounding could not be controlled, as the information was not available 
in our questionnaire. For example, exposure to indoor air pollution caused by smoke from 
cooking fire, which has been associated with cervical carcinoma [51]. Like in most 
developing countries, the use of firewood for cooking is highly common in Uganda. 
However, this would have affected both cases and controls. Another factor is the 
education level. However, a pooled analysis showed that there were no differences in 
HPV positivity by education level, and concluded that the excess of cervical cancer found 
in women with little education is not due to the excess of HPV prevalence, but rather by 
early events which may modify the cancer causing ability of HPV [52]. 
 
Our study was limited by the number of probes for HPV which could only allow us to 
type 25 HPV genotypes, and the relatively small number of HIV positive cases of SCC 
and in particular adenocarcinomas.  
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In addition, assessment of immunity was based only on CD4 counts, which reflects HIV 
infection on the systemic immune system. Although CD4 counts have been used before 
[53] it is difficult to know when immunodeficiency sets in. The statistical power for 
detecting cancer risk in subgroups of HIV-infected women was limited, in particular for 
adenocarcinoma. 
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Conclusions 
 
In conclusion, the OR for squamous cell carcinoma and adenocarcinoma of the cervix in 
Uganda were increased in women infected with HPV, in particular single HPV infections, 
infections with HPV16- and 18-related types, infections with high-risk HPV types, 
specifically with HPV16, 18 and 45. Cervical cancer was not statistically associated with 
HIV infection per se, and HIV positive women did not have a higher OR for cervical 
cancer in relation to most HPV types, except for low-risk and multiple infections in SCC.  
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Tables 
 
Table 1: Subjects’ enrolment and measurements. Invasive cervical cancer study in 
Kampala, Uganda 
 Cases % Controls % 
Women invited to participate          484 100.0 385 100.0 
Declined to participate                 66 13.6 22 5.7 
Incomplete questionnaires              41 8.5 44 11.4 
Diagnosis not confirmeda                         61 12.6 5 1.3 
Total preliminary recruitedb                           316 100.0 314 100.0 
Samples for HPV testingb  239c 75.6 309 98.4 
Samples for HIV testingb                                 281 88.9 308 98.1 
Combined HIV and HPV samplesb                  222 70.3 303 96.5 
 
a
 Diagnosis of invasive cervical cancer not confirmed by histology for cases; control 
women found with abnormal cervical smears (cervical intraepithelial neoplasia, CIN, not 
invasive cervical cancer) 
b
 Percent based on total recruited 
c
 In addition to these 239, 16 cases were beta-globin negative  and therefort excluded 
from all analyses 
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Table 2: Clinical and demographic characteristics of cases and controls. Invasive 
cervical cancer study in Kampala, Uganda 
 Casesa Controls 
N % b N % b 
Number of women   316  314  
Mean age years (SD) 47 11.5 41 12.5 
Mean age first intercourse (SD)        16 3.0 16 3.0 
Mean parity (SD)                      6.9 5.8 4.8 4.0 
Mean CD4 counts (SD)           722 375 843 389 
Ever used hormonal contraceptives 103 32.6 111 35.4 
HIV status (+)c  55  18.8 54 17.5 
Had attended school  207 65.5 271 86.3 
Ever smoked regularly   26 8.2 26 8.3 
Partner is a current smoker                    76 24.1 67 21.3 
Alcohol consumption 131 41.5 133 42.4 
History of sexually transmitted diseases                   148 46.8 137 43.6 
Ever had Pap smear                      6 1.9 13 4.1 
HPV tested                          239  75.6 309 98.4 
HPV detected                         222   92.9d 95 30.7d 
HPV not detected   17e 7.1d 214 69.3d 
 
a Number of women with: squamous cell carcinoma: 265, adenocarcinoma: 42, mixed 
histology: 5, other: 4  
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b Percent where applicable 
c
 HIV positivity based on available data for 293 cases and 308 controls 
d
 Percentage (%) of tested 
e
 Additional 16 invasive cervical cancer patients had available samples, but these were 
beta-globine negative, indicating poor sample quality, and therefore were excluded from 
all analyses 
39 
 
Table 3: Riska of squamous cell carcinoma of the cervix for different HPV types  
HPV type 
HPV+ Age adjusted 
 
N = 203 cases & 
309 controls 
Age and HIV adjusted 
 
N = 193 cases &  
303 controls 
Age, HIV and CD4 
adjusted 
N = 192 cases &  
296 controls 
Cases Controls OR 95% CI OR 95% CI OR 95% CI 
High-risk HPV 
Allb 183 54 64.5 35.4-126.6 84.7 43.5-181.6 82.3 42.2-176.8 
16 101 10 29.1 15.4-60.7 28.8 15.2-60.2 27.2 14.4-56.9 
18 39 8 9.6 4.6-22.3 8.9 4.2-20.6 8.3 4.0-19.2 
31 2 3 0.8 0.1-4.6 0.7 0.1-3.7 0.5 0.1-2.8 
33 4 5 1.3 0.3-4.7 1.2 0.3-4.4 1.4 0.3-5.6 
35 10 7 2.4 0.9-6.7 2.5 0.9-6.9 2.7 1.0-8.1 
39 3 1 3.7 0.6-38.9 4.2 0.7-44.4 4.2 0.7-44.2 
45 18 0 58.7 >7.9j 56.5 >7.6j 57.2 >7.7j 
51 2 8 0.8 0.2-2.7 0.5 0.1-2.1 0.5 0.1-2.1 
52 6 13 0.7 0.2-1.7 0.6 0.2-1.5 0.5 0.2-1.3 
56 2 4 0.9 0.2-4.6 1.0 0.2-4.7 1.1 0.2-5.5 
58 2 3 0.9 0.2-5.1 1.0 0.2-5.8 1.1 0.2-5.8 
59 1 2 0.7 0.1-6.5 0.8 0.1-7.4 0.8 0.1-7.4 
68/73 6 7 1.5 0.5-4.6 1.3 0.4-4.0 1.3 0.4-3.9 
Low-risk HPV 
Allc 5 24 0.5 0.2-1.0 0.3 0.1-0.8 0.3 0.1-0.7 
6 1 3 1.0 0.1-7.0 1.1 0.1-8.0 1.1 0.1-7.9 
11 0 2 0.5 <6.4k 0.4 <5.4k 0.3 <4.3k 
34 0 1 0.6 <11.1k 0.4 <7.5k 0.3 <5.3k 
40 0 1 0.7 <13.0k 0.8 <14.7k 0.8 <14.6k 
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42 0 0 4.1 >0.2j l l l l 
44 0 4 0.2 <2.2k 0.3 <2.5k 0.2 <2.5k 
53 0 4 0.1 <1.2k 0.1 <1.2k 0.1 <1.1k 
54 1 3 0.4 <2.5k 0.4 <2.8k 0.5 <2.9k 
66 0 5 0.4 <2.2k 0.1 <1.0k 0.1 <1.1k 
70 1 3 0.7 0.1-4.2 0.6 0.1-3.7 0.5 0.1-3.2 
74 2 4 1.0 0.1-4.2 0.9 0.2-4.6 0.8 0.1-3.8 
Single inf.d 168 49 33.3 20.2-56.7 31.5 19.1-54.0 31.0 18.7-53.5 
Multiple inf.e 15 20 1.3 0.7-2.7 1.2 0.6-2.4 1.1 0.5-2.3 
16- relatedf 123 36 11.6 7.5-18.5 11.9 7.6-19.0 11.4 7.2-18.3 
18- relatedg 66 16 9.4 5.3-17.4 8.9 5.0-16.5 8.6 4.9-16.1 
HPVXh 3 26 0.2 0.1-0.5 0.2 0.1-0.5 0.2 0.1-0.6 
Any HPVi  186 95 50.8 25.8-113.9 55.7 27.2-132.4 54.9 26.7-130.4 
 
a
 OR and 95% CI 
b High-risk HPV: 16, 18, 31, 33, 35, 45, 51, 52, 56, 58, 59, 68/73 
c
 Low-risk HPV: 6, 11, 34, 40, 42, 43, 44, 53, 54, 66, 70, 74 
d Single infection: infection with any of the HPV types above, except HPVX 
e Multiple infections: infections with at least two different HPV types, except HPVX 
f
 HPV16- related: includes HPV 16, 31, 33, 35, 52 and 58  
g
 HPV18- related: includes HPV 18, 45, 59 and 68 
h
 HPVX: Samples which could not be typed with any of the 25 genotypes abowe 
i Any HPV infection: infection with any of the HPV types above 
j
 Indicate only lower limit value of 95% CI 
k
 Indicate only upper limit value of 95% CI  
l Could not be estimated due to lack of cases with known HIV status 
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Table 4: Squamous cell carcinoma of the cervix according to different HPV types 
and HIV serology 
HPV types 
HIV Negative women HIV Positive women 
Cases 
(N = 162) 
Controls 
(N = 251) 
  Cases 
(N = 42) 
Controls 
(N = 52) 
  
HPV HPV   HPV HPV   
+ - + - ORa 95% CI + - + - ORa 95% CI 
High-riskb 142 10 35 216 76.4 38.8-165.6 41 1 19 33 132.3 >17.0j 
16 78 74 7 244   32.8 15.6-78.9 23 18 3 49 16.5 5.3-67.6 
18 27 125 2 249 22.3 7.1-111.8 12 29 6 46   2.9 1.0-9.1 
31 0 152   2 249 0.1 <1.5i 2 39 1 51 2.3 0.3-26.4 
33 4 148 2 249 2.5 0.5-14.8 0 41 3 49 0.2 <2.7i 
35 10 142 4 247 4.5 1.5-16.0 0 41 3 49   0.2 <2.0i 
45 13 139 0 251 41.8 >5.4j 5 36 0 52 17.1 1.8-2287 
Low-riskc 3 149 18 233 0.3 0.1-0.9 2 39 6 46 0.5 0.1-2.0 
Single inf.d 132 20 38 213 34.0 19.4-62.5 36 5 11 41 21.4 7.5-71.0 
Multiple inf.e 10 142 9 242 2.0 0.8-5.1 5 36 11 41 0.6 0.2-1.9 
16- relatedf 98 54 22 229 17.0 10.0-30.1 25 16 14 38 3.8 1.6-9.4 
18- relatedg 49 103 9 242   11.9 5.9-26.4 17 24 7 45 4.5 1.7-13.1 
Any HPVh 145 7   66 185    51.3 24.8-122.6 41 0 29 23 60.0 >7.7j 
 
a
 All odds ratios are age-adjusted 
b High-risk HPV: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73 
c
 Low-risk HPV: 6, 11, 34, 40, 42, 43, 44, 53, 54, 66, 70, 74 
d Single infection: infection with any of the HPV types above 
e Multiple infections: infections with at least two different HPV types 
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f
 HPV16- related: includes HPV 16, 31, 33, 35, 52 and 58 
g
 HPV18- related: includes HPV 18, 45, 59 and 68 
h Any HPV infection: infection with any of the HPV types above 
i
 Indicate only upper limit value of 95% CI 
j
 Indicate only lower limit value of 95% CI 
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Table 5: Adenocarcinoma of the cervix for different HPV typesa  
HPV type 
Number HPV+ 
 
Age adjusted 
 
Age and HIV adjusted Age, HIV and CD4 adjusted 
Cases Controls OR 95% CI OR 95% CI OR 95% CI 
High-risk HPV 
Allb 26 54 27.2 10.4-88.9 40.5 14.1-157.4 40.0 13.9-155.6 
16 10 10 11.6 4.3-31.8 14.5 5.2-42.6 13.8 4.9-40.2 
18 10 8 18.5 6.6-54.4 26.3 8.3-96.5 24.0 7.7-86.9 
31 1 3 2.2 0.2-16.1 2.6 0.2-19.6 2.6 0.2-19.2 
33 0 5 1.2 <12.2j 1.4 <14.6j 1.3 <14.1j 
35 0 7 0.8 <7.1j 0.9 <8.3j 0.8 <7.9j 
39 0 1 5.5 <108.6j 4.7 <92.5j 4.7 <92.5j 
45 4 0 297.4 >26.4k 248.3 >22.1k 247.8 >22.0k 
51 2 8 3.9 0.7-16.9 4.1 0.7-17.6 4.1 0.7-17.7 
52 0 13 0.3 <2.4j 0.4 <3.4j 0.3 <2.9j 
56 0 4 0.8 <11.0 1.0  <12.1j 1.0 <12.8j 
58 0 3 1.3 <15.5j 1.3 <14.9j  1.3 <14.9j 
59 0 2 0.9 <18.6j 1.1 <19.27j  1.1 <19.8j 
68/73 2 7 3.0 0.5-13.7 3.6 0.6-16.2 3.4 0.6-16.0 
Low-risk HPV 
Allc 1 24 0.6 0.1-2.4 0.6 0.1-2.7 0.6 0.1-2.6 
6 1 3 12.8 1.1-96.7 10.0 0.9-76.0 10.0 0.9-75.9 
11 0 2 3.7 <55.1j 4.6 <64.5j  3.8 <56.5j 
34 0 1 4.3 <82.4j 6.4  <161j 4.6 <126.4j 
40 0 1 5.3 <102.7j 4.5  <88.3j 4.5 <88.3j 
44 1 4 5.4 0.5-35.2 4.8 0.4-30.3 4.8 0.4-30.3 
53 0 4 0.7 <7.6j 0.8  <8.7j 0.8 <8.3j 
54 0 3 0.6 <7.4j 0.7  <8.0j 0.7 <8.0j 
66 0 5 0.9 <9.0j 1.2  <12.7j 1.0 <11.2j 
70 0 3 1.3 <15.3j 1.6  <17.7j 1.4 <16.0j 
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74 0 4 0.8 <11.1j 0.9  <11.9j 0.9 <11.5j 
Single inf.d 22 49 13.7 6.0-34.0 15.5 6.6-40.5 15.3 6.5-40.0 
Multiple inf.e 4 20 2.5 0.7-7.5 3.3 0.9-10.5 3.1 0.8-9.8 
16- relatedf 11 36 3.6 1.5-8.2 4.9 2.0-11.6 4.7 1.9-11.2 
18- relatedg 16 16 22.8 9.3-58.9 26.2 10.3-71.8 24.5 9.7-67.0 
HPVXh 0 26 0.2 <1.2b 0.2 <1.3b 0.2 <1.5b 
Any HPVi 26 95 12.9 5.0-41.8 18.7 6.6-71.6 18.6 6.6-71.2 
 
a
 Analysis conducted with 32 cases and 309 controls 
b High-risk HPV: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73 
c
 Low-risk HPV: 6, 11, 34, 40, 42, 43, 44, 53, 54, 66, 70, 74 
d Single infection: infection with any of the HPV types above, except HPVX 
e Multiple infections: infections with at least two different HPV types, except HPVX 
f
 HPV16- related: includes HPV 16, 31, 33, 35, 52 and 58 
g
 HPV18- related: includes HPV 18, 45, 59 and 68 
h
 HPVX: Samples which could not be typed with any of the 25 genotypes abowe 
i Any HPV infection: infection with any of the HPV types above 
j
 Indicate only upper limit value of 95% CI 
k
 Indicate only lower limit value of 95% CI 
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Table 6: Adenocarcinoma of the cervix according to different HPV types and HIV 
serology 
HPV types 
HIV Negative women HIV Positive women 
Cases 
(N = 28) 
Controls 
(N = 251) 
  Cases 
(N = 4) 
Controls 
(N = 52) 
  
HPV HPV   HPV HPV   
+ - + - ORa 95% CI + - + - ORa 95% CI 
High-riskb 24 3 53 216 39.5 13.6-153.8 2 0 19 33 8.8 0.7-1235 
16 8 19 7 244   11.0 3.6-34.2 2 0 3 49 108.2 >4.0i 
18 10 17 2 249 57.9 14.8-327.8 0 2 6 46   1.3 <20.8j 
31 1 26   2 249 2.8 0.2-24.2 0 2 1 51 6.0 <149.8j 
33 0 27 2 249 1.8 <23.7j 0 2 3 49 3.5 <71.4j 
45 4 23 0 251 251.3 >22.2i 0 2 0 52 k k 
Low-riskc 1 26 18 233 0.7 0.1-3.2 2 0 6 46 1.4 <19.8j 
Single inf.d 7 20 38 213 14.5 6.0-38.2 2 0 11 41 15.0 1.2-2086 
Multiple inf.e 4 23 9 242 5.0 1.3-16.9 2 0 11 41 0.9 <11.0j 
16- relatedf 9 18 22 229 4.3 1.6-10.5 2 0 14 38 12.8 1.0-1794 
18- relatedg 16 11 7 244   42.2 15.0-133.8 0 2 7 45 1.3 <17.8j 
Any HPVh 24 3   66 185    18.3 6.4-70.0 2 0 29 23 4.0 0.3-565.6 
 
a
 All odds ratios are age-adjusted 
b High-risk HPV: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73 
c
 Low-risk HPV: 6, 11, 34, 40, 42, 43, 44, 53, 54, 66, 70, 74 
d Single infection: infection with any of the HPV types above 
e Multiple infections: infections with at least two different HPV types 
f
 HPV16- related: includes HPV 16, 31, 33, 35, 52 and 58 
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g
 HPV18- related: includes HPV 18, 45, 59 and 68 
h Any HPV infection: infection with any of the HPV types above 
i
 Indicate only lower limit value of 95% CI 
j
 Indicate only upper limit value of 95% CI 
k
 Could not be estimated due to lack of cases with known HIV status 
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Table 7: Squamous cell carcinoma and adenocarcinoma of the cervix according to 
particular adjustment factors 
Adjustment factor 
Squamous cell carcinoma 
N = 246 cases, 308 controlsa 
Adenocarcinoma 
N = 39 cases, 308 controlsb 
OR 95% CI OR 95% CI 
Age 1.5 0.9-2.3 1.1 0.4-2.7 
Age + CD4 1.6 1.0-2.6 0.8 0.1-2.6 
Age + CD4 + HPV16 1.6 0.9-2.9 0.5 0.1-1.8 
Age + CD4 + HPV16-relatedc 1.4 0.7-2.4 0.5 0.1-1.6 
Age + CD4 + HPV18 1.4 0.8-2.4 0.3 <1.2j 
Age + CD4 + HPV18-relatedd 1.4 0.8-2.4 0.4 0.1-1.5 
Age + CD4 + High-risk HPVe 0.6 0.3-1.1 0.3 <0.9j 
Age + CD4 + Low-risk HPVf 1.9 1.1-3.2 0.8 0.2-2.6 
Age + CD4 + Single HPV 
inf.g 
1.2 0.6-2.4 0.5 0.1-1.7 
Age + CD4 + Multiple HPV 
inf.h 
1.8 1.1-3.0 0.6 0.1-2.0 
Age + CD4 + Any HPV inf.i 0.8 0.4-1.4 0.4 0.1-1.2 
 
a
 HIV positive: 48 cases, 54 controls 
b
 HIV positive: 5 cases, 54 controls 
c
 HPV16- related: includes HPV 16, 31, 33, 35, 52 and 58 
d
 HPV18- related: includes HPV 18, 45, 59 and 68 
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e High-risk HPV: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73 
f
 Low-risk HPV: 6, 11, 34, 40, 42, 43, 44, 53, 54, 66, 70, 74 
g Single infection: infection with any of the HPV types above 
h Multiple infections: infections with at least two different HPV types 
i Any HPV infection: infection with any of the HPV types above 
j
 Indicate only lower limit value of 95% CI 
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Abstract 
 
Background 
 Human Papillomavirus (HPV) detection results comparing paraffin embedded cervical 
tissue and other cervical specimens have been done with varying degrees of agreement. 
However, studies comparing freshly frozen specimens and paraffin embedded specimens 
of invasive cervical carcinomas are lacking. The aim of the study was to compare HPV 
detection using SPF10 broad-spectrum primers PCR followed by DEIA and genotyping 
by LiPA25 (version 1) between freshly frozen cervical tissue samples and paraffin 
embedded blocks of cervical tissue from the same patient. There were 171 pairs of 
paraffin embedded and freshly frozen samples analyzed from cervical carcinoma cases 
from Kampala, Uganda. 
Results 
88.9% (95% CI: 83.2%-93.2%) of paraffin embedded samples were HPV positive 
compared with 90.1% (95% CI: 84.6%-94.1%) of freshly frozen samples, giving an 
overall agreement in HPV detection between fresh tissue and paraffin embedded tissue at 
86.0% (95% CI: 79.8%-90.8%). Although the proportion of HPV positive cases in freshly 
frozen tissue was higher than those in paraffin blocks, the difference was not statistically 
significant (p > 0.05). In both types of tissues, single HPV infections were predominant, 
with HPV16 accounting for 47% of positive cases. Comparison in the overall agreement, 
taking into accounts not only positivity in general, but also HPV types, showed a 65% 
agreement (complete agreement of 59.7%, partial agreement of 5.3%) and complete 
disagreement of 35.0%. HPV detection in squamous cell carcinomas (SCC) and 
adenocarcinomas (ADC) was similar in fresh tissue or paraffin blocks (p ≥ 0.05).  
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p16 immunostaining in samples that had at least one HPV negative results showed that 24 
out of 25 cases had an over-expressed pattern. 
Conclusions 
HPV DNA detection was lower among ADC as compared to SCC. However, such 
differences were minimized when additional p16 testing was added, suggesting that the 
technical issues may largely explain the HPV negative cases.  
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Background 
 
Improved DNA retrieval methods have made possible the realization of gene analyses 
and viral genome identification in archival formalin fixed paraffin embedded (FFPE) 
tissues [1-4]. A number of methods have been developed over the past few years to detect 
the Human Papillomavirus (HPV), one of them being Short PCR Fragment-10 (SPF10) 
Line Probe Assay system (LiPA) [5,6]. This assay is based on the amplification of a 65-
bp region of L1 open reading frame. In order to validate the SPF10 LiPA assay using 
FFPE cervical samples, comparisons with other samples have been performed by some 
investigators [7,8] with good overall agreement. The overall agreement was generally 
high from these studies when cervical scrapes or cytological samples were used. Besides 
the generally lower detection of HPV in FFPE samples of cervical carcinoma, it has been 
shown that adenocarcinomas show an even lower positive rate compared to other 
histological types [9]. In view of these discrepancies, we thought it worthwhile to 
conduct a study to clarify whether the formalin fixation could differentially affect HPV 
detection according to the histological diagnosis. The main objective of the present study 
was to compare HPV detection using SPF10 broad-spectrum primers Polymerase Chain 
Reaction (PCR) followed by Deoxyribonucleic Acid Enzyme Immunoassay (DEIA) and 
genotyping by LiPA25 (version 1) between fresh cervical tissue samples and paraffin 
embedded blocks from the same patients, and also to assess whether there are differences 
in HPV detection between squamous cell carcinomas and adenocarcinomas. 
 
6 
 
Methods 
 
The materials for this study were obtained as part of a case-control study conducted at 
Mulago Hospital, Kampala, Uganda, which is the teaching hospital for the College of 
Health Sciences of Makerere University from September 2004 to December 2006. 
Tumour specimens were obtained from new incident cases of cervical carcinoma 
presented to the hospital as part of routine care. The tumour specimens were divided into 
two parts. One part was fixed in 10% formalin and entered in the register of Department 
of Pathology for processing (paraffin blocks), while the other part was stored at -80°C 
until transferred to the laboratory for analysis. In cases where the tissue was deemed to be 
very small, the whole tissue was formalin fixed and processed for histopathological 
diagnosis. Each case was given an identification number so that the paraffin block could 
be linked with the fresh specimen. The samples from the cases were all biopsies. The 
local histopathological diagnosis was performed by Michael Odida.  
 
HPV detection of cervical cancer cases in freshly frozen tissue  
HPV detection and genotyping in 195 freshly frozen cervical cancer specimens was 
performed at the DDL Diagnostic Laboratory in The Netherlands during the period from 
June to August 2008, also 1,5 up to 4 years after diagnosis. HPV detection was performed 
using SPF10 broad-spectrum primers PCR followed by DEIA and genotyping by 
LiPA25 (version 1). 
 
HPV detection of cervical cancer cases preserved in paraffin  
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The paraffin embedded blocks were prepared in Uganda for diagnostics purposes 
between September 2004 and December 2006 when the patients were recruited for the 
study. HPV detection and genotyping of 201 paraffin blocks was performed by 
pathologists at the Unit of Infections and Cancer at the Catalan Institute of Oncology 
(ICO) during January 2010, also 3 to 5.5 years after diagnosis. The detailed methods have 
been previously described in Odida et al. [10]. Briefly, at ICO the samples were 
processed following the next steps: (a) Re-embedding of the tissue material was done if 
necessary when the paraffin block was in poor condition for cutting; (b) Microtome 
sectioning of the specimens under non-contamination conditions and the sandwich 
technique were carried out to confirm an optimal number of sections to be used for DNA 
extraction and testing; (c) All cases were reviewed by a trained pathologist at ICO for 
diagnosis and assessing quality of the specimen before HPV testing. Cases difficult to 
classify, cases with a discordant diagnosis compared to the field diagnosis and all the rare 
histological types were further reviewed by two senior expert pathologists at ICO; (d) 
DNA was extracted under non-contamination protocols and aliquoted, and HPV testing 
was performed on each specimen using the SPF-10 broad spectrum primers PCR 
followed by DEIA. HPV DNA positive samples were subsequently analyzed by LiPA25 
(version 1: produced at Laboratory Biomedical Products, Rijswijk, The Netherlands), a 
reverse hybridization technique that detects 25 high-risk (HR) and low-risk (LR) HPV 
types (6, 11, 16, 18, 31, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 66, 
68, 70, 74). Both labs, DDL and ICO, performed routine cross-validation testing for 
SPF10, DEIA and LiPA with high agreement between them, concordant results of > 98% 
(data not shown). 
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Since the number of samples received at DDL and ICO differ, the comparison was 
performed based on the cases that were HPV analyzed in both laboratories, n = 171. Data 
generated at Makerere Hospital (original pathological diagnosis), at DDL (HPV detection 
in freshly frozen tissue) and at ICO (pathological diagnosis and HPV detection in paraffin 
blocks) were merged into one dataset using the common identifier first provided by 
Makerere University. A descriptive analysis of global HPV positivity and HPV types 
globally and by histological diagnosis of cervical carcinoma and type of specimens was 
performed. Global HPV detection concordance analysis, in terms of positive or negative 
result was done to assess differences between the fresh and paraffin, as well as between 
squamous cell carcinoma (SCC) and adenocarcinomas (ADC). 
Further analysis for the overall agreement, taking into account not only general positivity 
but also HPV types, was done to assess the exact agreement between the two samples. 
The agreement was classified as complete, partial or complete disagreement according to 
the definitions below.  
Complete agreement: The result is exactly the same (same HPV single type, or same 
multiple types or HPV negative result). 
Partial agreement: The cases have at least one identical type. 
Complete disagreement: The cases are totally different (different type or HPV positive-
HPV negative). 
 
p16 Immunohistochemistry 
It has been largely described that p16 over-expression is a surrogate marker of HPV E7 
oncoprotein-mediated catabolism of pRb in premalignant and malignant lesions of the 
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cervical mucosa. In the present study, p16 immunostaining was performed in a selected 
number of paraffin embedded tissue from cancer cases in order (1) to obtain more insight 
regarding the HPV oncogenic role in the discordant cases and (2) to discard non-HPV 
related cancers in the concordant HPV negative cases. The cases included in this analysis 
were all HPV discordant cases (n = 24), all concordant HPV negative cases (n = 6) and a 
random sample of approximately a 10% of the concordant HPV positive cases (n = 15). 
p16INK4a was detected using the CINtec histology kit (clone E6H4, MTM Laboratories, 
Heidelberg, Germany), following the manufacturer’s protocol. In each series, a negative 
control and a positive control consisting of an invasive cervical carcinoma were included. 
The percentage of stained cells (-: < 5%; +: 5-25%; ++: 26-75%; +++: > 75%) and the 
pattern (focal/diffuse) was recorded, and a positive case was considered when the 
percentage was 5 and above (++ or more) with a diffuse pattern. 
 
Statistical tests 
The Kappa statistics and McNemar test were used to test the statistical significance of 
HPV detection between fresh samples and paraffin blocks, while the Chi square test and 
Fisher exact test were used to test the statistical significance of HPV detection between 
SCC and ADC in both fresh and paraffin blocks. Where appropriate, 95% confidence 
intervals (CI) were computed, and the level of statistical significant test was set at 0.05. 
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Results 
 
Overall agreement between fresh tissue specimens and paraffin embedded tissue 
Overall, 154 of freshly frozen tissue were positive for HPV (90.1%, 95% CI: 84.6%-
94.1%) and 152 of tissue in paraffin blocks were HPV positive (88.9%, 95% CI: 83.2%-
93.2%), giving an overall agreement in HPV detection between fresh tissue and paraffin 
blocks at 86.0% (95% CI: 79.8%-90.8%), which was statistically significant (Kappa 
Index = 0.26, p = 0.001). Although the proportion of HPV positive cases in fresh tissue 
was higher than those in paraffin blocks, the difference was not statistically significant 
(McNemar test, p > 0.05). The details are shown in Table 1. 
          
In both types of tissues, single HPV infections were predominant. Only one case has been 
DEIA positive, and LiPA negative (HPVX, unknown type) and has been detected in 
paraffin embedded tissue. The proportion of multiple HPV infections was higher in 
freshly frozen tissue cases than tissue in paraffin blocks. However, the differences 
between both kinds of tissues were not statically significant (all p-values are > 0.05). The 
details are shown in Table 2. 
 
HPV types in single infections 
In both kinds of tissue, HPV16 was the most frequently identified in 47.4% among HPV 
positive cases. The proportion of HPV33, HPV52 and HPV58 were almost identical. A 
higher proportion of HPV18 and HPV35 were identified in paraffin blocks compared to 
fresh tissue and, conversely, a higher proportion of HPV45, HPV68 or 73, HPV51 and 
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HPV39 in fresh tissue. HPVs 66 and 31 were only identified in fresh tissue and HPVs 59, 
11 and HPVX were only detected in paraffin embedded tissue. The details are shown in 
Figure 1. 
 
HPV types in multiple infections 
Table 3 shows HPV type distribution of multiple types in freshly frozen tissue versus 
tissue in paraffin blocks. In 11 out of the 16 cases described in table 4, the HPV result 
matched at least for one of the HPV types. 
 
HPV types agreement between fresh tissue specimens and paraffin embedded 
specimens 
When analyzed for the overall agreement, also taking into account HPV types, complete 
agreement was found to be 59.7% (complete agreement in single HPV types: 55.0%, 
complete agreement in multiple types: 1.2%, complete agreement in HPV negativity: 
3.5%), partial agreement: 5.3% and complete disagreement: 35.0%.  
 
HPV detection concordance by histological type of cervical carcinoma 
For performing the HPV detection concordance analysis stratified by histological 
diagnosis, we selected the cases that had a concordant histological diagnosis between the 
local and ICO pathology evaluation: SCC (n = 130) and ADC (n = 7).  
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Sqamous cell carcinoma 
The HPV positivity in freshly frozen tissue was 91.5% (95% CI: 85.4%-95.7%), and the 
corresponding HPV positivity in paraffin embedded tissue was 93.1% (95% CI: 87.3%-
96.8%), giving an overall agreement in HPV detection between fresh tissue and paraffin 
embedded tissue of 90.8% (95% CI: 84.4%-95.1%), which was statistically significant, 
although the strength of concordance is weak (Kappa Index of agreement of 0.35; p < 
0.001). Although identifying a higher HPV positivity in tissue from paraffin blocks, this 
difference was not statistically significant (McNemar test, p > 0.05).  
 
Adenocarcinoma 
The HPV positivity in freshly frozen tissue was 85.7% (95% CI: 42.1%-99.6%), and the 
HPV positivity in paraffin embedded tissue was 71.4% (95% CI: 29.0%-96.3%), giving 
an overall agreement in HPV detection between fresh tissue and paraffin blocks: 85.7% 
(95% CI: 42.1%-99.6%), which was not statistically significant (Kappa Index of 
agreement of 0.59; p > 0.05). Although identifying a higher HPV positivity in fresh 
tissue, this difference was not statistically significant (McNemar test, p > 0.05).  
 
HPV detection concordance between histological types of cervical carcinoma 
Comparing HPV positivity by diagnosis and tissue preservation, adenocarcinomas were 
more likely to be HPV negative than SCC, both in freshly frozen tissue and paraffin 
embedded tissue. This difference was higher in paraffin embedded tissue than in fresh 
tissue (21 percentage points difference versus 6, respectively), although the differences 
were not statistically significant (p > 0.05), as is shown in Table 4. 
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p16 Immunostaining results 
45 cases were included in the p16 analysis. From these cases, p16 was successfully 
performed in 40 (88.9%). In the other 5 cases, there was no tumour in the p16 slide 
(11.1%). All cases except one showed a positive p16 over-expressed pattern (Table 5). 
Only one case, an adenocarcinoma NOS (subtype: not other specified), was HPV 
negative in both fresh and paraffin embedded tissue and also showed a p16 negative 
pattern, suggesting that maybe it is not HPV related or it is a case with an endometrial 
origin (not cervical). 
 
14 
 
Discussion  
 
The goal of this study was to examine whether HPV genotyping on FFPE invasive 
cervical carcinoma specimens give comparable results with freshly frozen specimens 
obtained from the same patient simultaneously. Our study suggests that detection of HPV 
using SPF10 with LiPA technology using formalin fixed paraffin embedded tissues gives 
comparable results to freshly frozen specimens for HPV detection in general (Kappa 
index 0.26, p = 0.001), see Table 1, but is not so good for specific HPV types detection 
(p-value > 0.05). Some previous studies which compared the paraffin embedded tissue 
with other samples found high agreement [7,8,11]. However, these studies used 
exfoliated cells or cervical scrapes and not freshly frozen specimens. Besides, these were 
cases of preneoplastic lesions, not invasive cervical carcinoma. A study which compared 
FFPE tissue with cervical scrapes from women with invasive cervical carcinoma found 
very high HPV type specific concordance [12]. However, the number of samples studied 
was small, and also the method of detection was GP5+/6+ primers.  
 Another interesting observation was the negative HPV results in both freshly frozen 
specimens and FFPE tissues. Our analysis of p16 immunostaining in samples with at least 
one negative result showed that all but one sample tested p16 positive, suggesting that the 
cases are HPV mediated and that the most probable reason for not detecting the virus is 
related to viral, specimen preservation or technical issues such as denatured DNA by 
alkali [13] or by formalin fixation [14]. For specific HPV types, if one considers fresh 
specimens as gold standard, then discordance in HPV results from FFPE specimens could 
be due to a number of explanations. One is that formalin fixation could have denatured 
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the tissue. It is known that DNA extracted from FFPE tissues are usually at low 
concentration and fragmented [14,15]. Another alternative view is reduced sensitivity 
detection of some HPV types in paraffin specimens, especially types 42, 16, 18, 39, 56, 
58, 59 and 66 [16-18]. A third possibility, which may be applicable to discordance in 
multiple infections is due to competition between different HPV genotypes [19]. It is 
conceivable that lower discordance rates could be obtained by reducing the duration of 
fixation in buffered formalin. 
The low detection of HPV in adenocarcinoma in both types of specimens is also of 
interest. A number of previous studies have also found low detection of HPV in 
adenocarcinoma of the cervix [9,20,21]. Plausible explanations are: (a) that some cervical 
tumours may be of endometrial origin and are therefore HPV negative [22]; (b) that some 
cervical adenocarcinomas may not be related to HPV (such as minimal deviation 
adenocarcinomas) [21,23]; (c) low viral load; (d) fewer episomal copies; (e) or loss of 
viral genome during integration in cervical adenocarcinoma [24]. Though some 
investigators found a high positive rate which they attributed to higher diagnostic 
accuracy and exclusion of non cervical tumours [25].  
Our results have some implications. For areas with low resources, use of FFPE samples 
for HPV detection is feasible, especially HPV testing for clinical management of women 
with abnormal smears. In case a biopsy is taken, the paraffin embedded tissue could be 
referred to laboratory for HPV testing. This would make use of HPV results, whether for 
prognosis or detection of progression of cervical lesions like high-grade squamous 
intraepithelial lesion (HSIL) possible in many areas. However, there would be a need to 
have standard protocols so that fixation time is controlled. In some situations, the 
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preference for fresh or paraffin tissue will depend on the amount of available tissue and 
the questions being addressed.  
Our study had some strengths. Compared with a recent study which compared the use of 
cervical scrapes and tissues from women with cervical carcinoma [12], our sample size 
was big. The specimens were analyzed in two different laboratories blindly using the 
same HPV detection method. The SPF10 and LiPA technology are quite sensitive and 
specific for HPV [16]. The study also has, however, some limitations. The piece of tissue 
used was divided in two, and half was used to prepare the paraffin blocks and half kept as 
freshly frozen tissue for HPV genotyping. Thus, they were not exactly the same tumour 
materials, but pieces of tissue adjacent to each other. Moreover, a small number of 
adenocarcinomas limits the use of statistical tests. 
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Conclusions 
 
There were no differences in HPV positivity between freshly frozen tissue and paraffin 
embedded tissue in general, but for specific types, only 65% of the cases had complete or 
partial agreement on the HPV detection. HPV DNA detection was lower in ADC as 
compared to SCC, the difference being higher in paraffin blocks than in fresh tissue (21 
percentage points difference versus 6, respectively; p > 0.05). However, such differences 
were minimized when additional p16 testing was added, suggesting that technical issues 
largely explain the HPV negative cases. 
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Figure legends 
Figure 1 - HPV type distribution of single types in fresh tissue versus paraffin block 
 
Percentiles (%) of single/multiple/X HPV types among HPV positive cases 
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Tables  
 
 Table 1 - HPV detection in fresh tissue versus paraffin block 
 
 Paraffin block 
Total 
Positive Negative 
N % a N % a N % a 
Fresh tissue 
Positive 141 82.5b 13 7.6 154 90.1 
Negative 11 6.4 6 3.5b 17 9.9 
 Total 152 88.9 19 11.1 171 100 
 
a
 Percentage of cell number among all the cases (171) 
b
 Concordant results  
Concordance analysis-Kappa Index: value of the index 0.26; p = 0.001 
McNemar test: p > 0.05 
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Table 2 - HPV detection in fresh tissue versus paraffin block: single/multiple/HPVX 
types 
 
HPV detection 
Fresh tissue Paraffin block 
Number 
of cases 
% 95% CIb 
Number 
of cases 
% 95% CIb 
Cases HPV analyzed 171 100  171 100  
HPV negative 17 9.9 (5.9-15.4) 19 11.1 (6.8-16.8) 
HPV positive 154 90.1 (84.6-94.1) 152 88.9 (83.2-93.2) 
Single HPV typesa 143 92.9 (87.6-96.4) 144 94.7 (89.9-97.7) 
Multiple HPV typesa 11 7.1 (3.6-12.4) 7 4.6 (1.9-9.3) 
HPV X – unknowna 0 0.0 (0.0-2.4) 1 0.7 (0.0-3.6) 
 
CI, Confidence Interval;  
a
 Number of single/multiple/X among HPV positive cases;  
b
 For all comparisons: p-value > 0.05 
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Table 3 - HPV type distribution of multiple types in fresh tissue versus paraffin 
block 
 
Fresh tissuea Paraffin blockb 
HPV 18 & 74 HPV 18 & 74 
HPV 16 & 52 HPV 16 & 52 
HPV 16 HPV 16 & 35 
HPV 18 HPV 16 & 18 
HPV 18 HPV 18 & 56 
HPV 45 HPV 45 & 54 
HPV 16 & 45 HPV 16 
HPV 18 & 31 HPV 18 
HPV 18 & 70 HPV 18 
HPV 59 & 74 HPV 59 
HPV 39 HPV 16 & 39 
HPV 16 & 18 HPV 59 
HPV 18 & 52 HPV 16 
HPV 6 & 44 & 45 HPV 18 
HPV 39 & 51 & 52 HPV 33 
HPV 6 & 45 HPV negative 
 
a
 Multiple HPV cases, N = 11 
b
 Multiple HPV cases, N = 7 
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Table 4 - HPV detection in fresh tissue versus paraffin block according to 
histological diagnosis 
 
HPV 
detection 
SCC 
N = 130 
ADC 
N = 7 
Number of 
cases 
% 95% CI 
Number of 
cases 
% 95% CI 
Fresh tissue 119 91.5 (85.4-95.7) 6 85.7 (42.1-99.6) 
Paraffin 
blocks 
121 93.1 (87.3-96.8) 5 71.4 (29.0-96.3) 
 
ADC, adenocarcinoma; CI, confidence interval; SCC, squamous cell carcinoma;  
For all comparisons: p-value > 0.05 
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Table 5 - Results of p16 expression by HPV results 
 
HPV results 
fresh/paraffin preservation 
p16 
Total - ++ +++ 
N % N % N % N % 
Concordant HPV negative 1a 16.7 1b 16.7 4e 66.7 6 100 
Concordant HPV positive 0 0.0 1c 6.7 14f 93.3 15 100 
Fresh HPV positive, Paraffin HPV negative 0 0.0 0 0.0 9g 100 9 100 
Fresh HPV negative, Paraffin HPV positive 0 0.0 2d 20 8h 80 10 100 
Total 1 2.5 4 10 35 87.5 40 100 
 
p16-: < 5% stained cells; p16++: 26-75%; p16+++: > 75% 
Histologies:  
a adenocarcinoma NOS (not other specified) 
b undifferentiated carcinoma 
c undifferentiated carcinoma 
d 1 adenocaricnoma and 1 undifferentiated carcinoma 
e 4 squamous cell carcinoma 
f 13 squamous cell carcinoma and 1 undifferentiated carcinoma 
g 5 squamous cell carcinoma, 1 adenocarcinoma and 3 undifferentiated carcinoma 
h 7 squamous cell carcinoma, 1 adenocarcinoma 
 


